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Abstract 
Allele-specific expression (ASE) analysis, which quantifies the degree of allelic expression imbalance 
between two alleles in a diploid individual, has become a powerful tool for identifying gene expression 
variations that underlie phenotypic differences among individuals. ASE is driven by cis-regulatory variants 
located near a gene. Since the two alleles used to measure ASE are expressed in the same cellular 
environment and genetic background, they can serve as internal controls and eliminate the influence of 
trans-acting genetic and environmental factors. Existing ASE detection methods analyze one individual at 
a time, therefore not only wasting shared information across individuals, but also posing a challenge for 
interpretation of results across individuals. To overcome these limitations, my dissertation focused on 
developing statistical methods for ASE analysis using RNA sequencing (RNA-seq) and single-cell RNA-
seq (scRNA-seq) data. In the first project, I developed ASEP, a mixture model with subject-specific random 
effect to detect gene-level ASE across individuals in a population under one condition, as well as ASE 
difference between two conditions. Since ASE patterns may vary across cell types, to better identify 
cellular targets of disease, in the second project, I developed BSCET to characterize cell-type-specific ASE 
in bulk RNA-seq data by incorporating cell type composition information inferred from external scRNA-
seq data. By modeling covariate effect, BSCET can also detect genes whose cell-type-specific ASE are 
associated with clinical factors. Since having accurate cell type proportion estimate is critical for BSCET, 
in order to accurately estimate cell type proportions from heterogeneous bulk tissue RNA-seq samples, in 
the third project, I developed MuSiC2, an iterative weighted non-negative least squares regression 
method, to deconvolve cell types in multi-condition bulk tissue RNA-seq data using scRNA-seq data from 
a single condition as reference. With the growing popularity of RNA-seq and scRNA-seq, I believe 
methods developed in my dissertation will provide a set of valuable tools for transcriptomics research. 
Results from analyses using these tools will offer insights on gene regulation and elucidate its 
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ABSTRACT





Allele-specific expression (ASE) analysis, which quantifies the degree of allelic expression imbal-
ance between two alleles in a diploid individual, has become a powerful tool for identifying gene
expression variations that underlie phenotypic differences among individuals. ASE is driven by cis-
regulatory variants located near a gene. Since the two alleles used to measure ASE are expressed
in the same cellular environment and genetic background, they can serve as internal controls and
eliminate the influence of trans-acting genetic and environmental factors. Existing ASE detection
methods analyze one individual at a time, therefore not only wasting shared information across
individuals, but also posing a challenge for interpretation of results across individuals. To overcome
these limitations, my dissertation focused on developing statistical methods for ASE analysis using
RNA sequencing (RNA-seq) and single-cell RNA-seq (scRNA-seq) data. In the first project, I devel-
oped ASEP, a mixture model with subject-specific random effect to detect gene-level ASE across
individuals in a population under one condition, as well as ASE difference between two conditions.
Since ASE patterns may vary across cell types, to better identify cellular targets of disease, in the
second project, I developed BSCET to characterize cell-type-specific ASE in bulk RNA-seq data by
incorporating cell type composition information inferred from external scRNA-seq data. By mod-
eling covariate effect, BSCET can also detect genes whose cell-type-specific ASE are associated
with clinical factors. Since having accurate cell type proportion estimate is critical for BSCET, in or-
der to accurately estimate cell type proportions from heterogeneous bulk tissue RNA-seq samples,
in the third project, I developed MuSiC2, an iterative weighted non-negative least squares regres-
sion method, to deconvolve cell types in multi-condition bulk tissue RNA-seq data using scRNA-seq
data from a single condition as reference. With the growing popularity of RNA-seq and scRNA-seq,
I believe methods developed in my dissertation will provide a set of valuable tools for transcrip-
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tomics research. Results from analyses using these tools will offer insights on gene regulation and
elucidate its relationship to human diseases.
v
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The central dogma of molecular biology characterizes the flow of genetic information, from DNA to
RNA, and to functional product, protein. During this process, DNA is first transcribed into RNA, and
subsequently translated into protein. DNA sequences can vary across individuals, a phenomenon
known as genetic variation. Variations in the human genome can alter gene expression, which may
explain phenotypic differences among individuals. Genetics studies have played an instrumental
role in uncovering biological pathways and elucidating therapeutic targets of human diseases.
The most common type of genetic variations is single nucleotide polymorphisms (SNPs). In the
past decade, genome-wide association studies (GWAS) have been successful in identifying candi-
date loci for complex human diseases and traits. In such a study, researchers aim to identify the
association between genetic variants and phenotypes of interest across individuals. To date, over
10,000 significant associations have been reported between genetic variants and complex traits
across a variety of diseases (Visscher et al., 2012, 2017). Some of the GWAS findings have led to
known drug targets. For example, the E23K variant of gene KCNJ11 has been found to increase
the risk of type 2 diabetes and led to the discovery of drug Glyburide (Gloyn et al., 2003; Visscher
et al., 2017).
Despite the impressive success for disease susceptibility loci discovery, few, if any, results from
GWAS have led to the delivery of new therapies (Tam et al., 2019). The association peaks of
GWAS typically cover a handful of candidate genes, but rarely pinpoint the causative variants as
the identified SNPs are often correlated with an unknown causal genetic variant, a phenomenon
known as linkage disequilibrium (LD) (Wangler, Hu, and Shulman, 2017). Further complicating
the picture, we now know that most GWAS signals are likely the results of regulatory variants that
impact gene expression, rather than amino acid changes (Lonsdale et al., 2013). To enhance our
understanding of non-coding genomic regulatory sequences, additional studies are required to find
causative genes.
A commonly used approach to understand the functional roles of GWAS findings is expression
quantitative trait loci (eQTL) analysis (Aguet, Brown, Castel, et al., 2017; Nica and Dermitzakis,
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2013). Studies have found that many GWAS identified SNPs are significantly enriched for eQTLs,
compared to control SNPs matched by allele frequencies (Nicolae et al., 2010). An eQTL is a
genetic locus that explains the variation in gene expression, which may in turn lead to phenotypic
differences. Standard eQTL analysis involves a direct association test, mostly through linear re-
gression, between genetic markers in cis (within a preselected interval of the gene-of-origin) or in
trans (distant from gene of origin) and gene expression variation measured in tens or hundreds
of individuals (Nica and Dermitzakis, 2013). The initial wave of eQTL studies employed microar-
rays to measure genome-wide gene expression, where a microarray is typically a glass slide on to
which DNA molecules are fixed in an orderly manner at specific locations called spots (Dubitzky
et al., 2003). With the recent advance in next generation sequencing technologies, researchers
have started to employ RNA sequencing (RNA-seq) data for eQTL analysis. Compared to mi-
croarray data, RNA-seq is platform-independent, less noisy, can characterize gene expression with
higher sensitivity and specificity, and allows the detection of novel transcript variations (Majewski
and Pastinen, 2011; Wang, Gerstein, and Snyder, 2009).
To date, most eQTL studies have been performed in heterogeneous tissues, containing cells from
diverse cell types. However, in a multi-cellular organism, cells from different cell types may ex-
press different sets of genes, although they all contain the same DNA (Lawlor et al., 2017; Xu
et al., 2014). Studies have collectively emphasized the cell-type-specific nature of eQTLs, where
29%–80% of the eQTLs are cell type specific (Dimas et al., 2009; Lonsdale et al., 2013; Zhang
et al., 2018). To understand gene expression in a cell-type-dependent manner, studies have been
proposed to characterize cell-type-specific eQTLs. For example, with the rapid progress in single-
cell RNA sequencing (scRNA-seq) technologies, researchers can now characterize transcriptomics
of individual cells. eQTLs can therefore be directly inferred within each cell type using large scale
scRNA-seq data (Wijst et al., 2018). Even without large scale single-cell data, cell-type-specific
eQTLs can still be inferred using bulk RNA-seq data by adjusting for cell type composition as in-
teraction terms when modeling the relationship of gene expression and SNP genotype(Donovan
et al., 2020).
Although eQTL analysis has successfully uncovered functional variants that regulate gene expres-
sion, a typical eQTL analysis only tells local versus distal association (Dixon et al., 2007; Gilad,
Rifkin, and Pritchard, 2008). The cis- and trans-eQTLs defined in the vast majority of eQTL stud-
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ies performed in the last decade are surrogates for the true definition of cis- and trans-regulatory
effects, where the cis- affects gene expression in an allele-specific manner while the trans- affects
gene expression in an allele independent manner (Nica and Dermitzakis, 2013). The lack of explicit
information on distinguishing cis- versus trans- makes eQTL studies difficult to directly link genetic
variants to the underlying gene regulation mechanism (Schliekelman, 2008).
To identify cis-regulated gene expression variations, analysis of allele-specific expression (ASE)
has been proposed. However, due to computational challenges, effective statistical methods that
can fully utilize the RNA-seq data for ASE detection are still in need. In this dissertation, I present
a series of methods that address statistical questions raised in ASE analysis: 1) gene-level ASE
detection across individuals in a population; 2) cell-type-specific ASE analysis across individuals;
and 3) cell type deconvolution for multi-condition bulk RNA-seq data. I will first briefly introduce
the motivation of my dissertation work by describing the ASE analysis and cell type deconvolution
algorithms, and then outline the three projects presented in this dissertation.
1.1. Allele-specific expression
Allele-specific expression (ASE; also called allelic expression imbalance) analysis is an important
tool for directly associating cis-regulatory genetic variants with human diseases and traits. ASE
quantifies the expression imbalance between paternal and maternal alleles of a gene in a diploid
individual, captured by RNA-seq read counts of two alleles over heterozygous SNPs (Sun and Hu,
2013). In the absence of ASE, the two alleles are expected to be equally expressed and the ratio of
RNA-seq reads between the two alleles is approximately 1:1. The use of allelic expression in ASE
analysis is advantageous over the use of total expression of the two alleles in eQTL study because
the two alleles are expressed in the same cellular environment, providing an internal control for
each other and, consequently, eliminating the influence of trans-acting genetic and environmental
factors (Pastinen, 2010). Stemming from the fact that allelic variations are determined within each
individual, instead of capturing variations in total gene expression between individuals as in eQTL
analysis, ASE analysis has higher sensitivity and precision for detecting cis-acting regulatory SNPs.
A study has reported that up to 8-fold more samples are required for eQTL mapping to reach the
same statistical power as that obtained by ASE analysis (Almlöf et al., 2012).
Although RNA sequencing allows the characterization of allelic gene expression, the short RNA-seq
reads are prone to technical biases, such as mapping uncertainty, i.e., reads may not be uniquely
3
mapped to a single locus, PCR amplification bias that introduces duplicate reads, GC content bias
where more (or less) reads tend to come from regions with higher GC content etc. (Castel et al.,
2015). Most importantly, when aligning reads to the reference genome, reads perfectly matching
the reference genome were assigned to the reference allele, whereas reads that contain the non-
reference allele may fail to map uniquely or map to an incorrect location in the genome. Therefore,
the assignment favors the reference allele and can potentially bias the relative ASE (Stevenson,
Coolon, and Wittkopp, 2013). To reduce bias in ASE analysis, various bias removing strategies
have been developed for RNA-seq data processing (Auwera et al., 2013; Rozowsky et al., 2011;
Van et al., 2015), among which WASP (Van et al., 2015) is perhaps the most popular tool for
unbiased allele-specific read mapping as it yields low error rate and is flexible in working with other
read aligners.
One of the most widely used methods for ASE detection is the binomial test, employed by Allele-
Seq (Rozowsky et al., 2011), which tests for allelic expression imbalance at each SNP. However,
in real studies, a gene is likely to have more than one SNP showing ASE, highlighting the impor-
tance of aggregating expression information across multiple SNPs in the same gene. To jointly
consider multiple SNPs, haplotype phasing information is required to properly align the two alle-
les of each SNP to the paternal and maternal haplotypes. With haplotypes inferred from DNA
genotype data, Pickrell et al. (2010) summed read counts across SNPs within the same gene and
detected ASE at gene level; Skelly et al. (2011) developed a hierarchical Bayesian model incorpo-
rating phased SNP-level information for gene-level ASE detection. However, as most studies do
not have DNA genotype data available, the haplotype phasing information is often not observed.
Therefore, utilizing pseudo haplotype phasing derived from RNA-seq reads, Mayba et al. (2014)
proposed MBASED, a meta-analysis based method, for gene-level ASE detection. Edsgärd et al.
(2016) developed GeneiASE that aggregates SNP-level ASE effects to the gene-level ASE without
the requirement of known haplotypes. However, all of the above-mentioned methods detect ASE
within each individual. As ASE is often shared across individuals, to empower the detection as
well as ease the result interpretation across individuals, effective statistical models are needed to
combine both multi-SNP and multi-individual information when detecting ASE. Yet, to date, none of
the existing methods can achieve both.
In addition to gene-level ASE detection using samples from a single condition, methods have been
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developed to detect ASE difference between two conditions, e.g., normal vs. cancer tissues, for
the discovery of causative cis-regulatory variants that drive disease onset/progression (Edsgärd
et al., 2016; Mayba et al., 2014). Moreover, with the development of single-cell RNA sequencing
technologies, Darby et al. (2020) recently presented a workflow, scHLAcount, to detect ASE within
each cell type. Compared to bulk tissue RNA-seq data, scRNA-seq data are not only more costly
to generate, but also noisier for analysis. Therefore, it is desirable to have statistical methods that
can decipher cell-type-specific effect by leveraging information provided by bulk RNA-seq data.
In summary, ASE analysis is a valuable tool for exploring gene expression variation and the regu-
latory mechanisms underlying human diseases. Given the emerging availability of high-throughput
RNA-seq data, it is important to develop powerful statistical methods that can efficiently extract
information from the existing RNA-seq data to learn a comprehensive picture of molecular mecha-
nisms underlying ASE.
1.2. Cell type deconvolution
Heterogeneous tissues are frequently collected and sequenced for analysis of the transcriptome of
gene expression patterns. The heterogeneity of RNA-seq data induced by cell type composition
variations has made it difficult to distinguish how much of gene expression variability observed at
the bulk tissue level is due to shifts in cell type composition and how much is due to differences in
cell-type-specific gene expression (Gong and Szustakowski, 2013). The importance of accounting
for cell type composition in high-throughput data analyses has been well-recognized (Kamme et
al., 2003; Li and Wu, 2019; Zheng et al., 2017). For example, Donovan et al. (2020) proposed to
include cell type proportions in eQTL analysis to account for cell type composition difference across
subjects. Shen-Orr et al. (2010) included estimated cell type proportions in differential expression
analysis comparing whole-blood samples between different kidney transplant conditions, i.e., stable
post-transplant recipients vs. recipients with acute transplant rejection, and this analysis revealed
differentially expressed genes that are otherwise undetectable. Adjusting for cell type composition
with RNA-seq samples has become increasingly important in elucidating cell type contributions to
complex human diseases and traits.
The recent advance in scRNA-seq has enabled the characterization of gene expression for indi-
vidual cells. Although single-cell analysis can exploit cell-type-specific gene expression and cell
type composition that can help dissect the mechanisms underlying complex diseases, generating
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scRNA-seq data for a large number of samples is still expensive and therefore limits its application
in clinical research. Furthermore, scRNA-seq is noisy and cannot fully reflect the cell type com-
position of the bulk tissue. This is because dissociating cells from the solid tissue can generate
biased recovery of cell types, mainly driven by technical challenges, such as excessive cell death,
incomplete cell dissociation or destruction of cell morphological and positional information (Wang
et al., 2019; Zhou and Pu, 2016).
Gene expression in bulk tissue can be expressed as weighted sum of cell-type-specific gene ex-
pression (a.k.a signature matrix), with the weights equal to cell type proportions in the bulk tissue.
A number of computational tools based on deconvolution algorithms have been proposed to infer
cell type composition in bulk RNA-seq samples. These methods mainly fall into two categories
depending on whether a set of pre-selected cell-type-specific marker genes are required when
building the signature matrix. With pre-specified marker genes, for example, CIBERSORT, a sup-
port vector regression-based deconvolution framework for microarray data, has shown to be highly
robust to data noise and performed well for discriminating closely related cell types (Newman et al.,
2015). Bseq-sc extends CIBERSORT to RNA sequencing and uses scRNA-seq data to infer the
cell-type-specific gene expression matrix (Baron et al., 2016). Without pre-selecting marker genes,
for example, using all genes shared between the bulk and single-cell RNA-seq reference data, Mu-
SiC employs a weighted non-negative least squares (W-NNLS) regression for the deconvolution,
which up weighs genes with consistent expression cross subjects (Wang et al., 2019).
All methods described above assume a direct proportional relationship between the single-cell
reference and bulk mixture. However, this assumption may not hold due to the use of distinct tech-
nologies when generating the bulk and single-cell data (Jew et al., 2020). Recently, Bisque (Jew
et al., 2020) and CIBERSORTx (Newman et al., 2019) have shown improved performance as com-
pared to existing deconvolution methods. CIBERSORTx implemented additional gene expression
transformations to minimize platform-specific variation between single-cell signature matrix and
bulk RNA-seq data. Despite the improvement, like all other deconvolution methods, the cell-type-
specific gene expression is reconstructed using only one single-cell reference. Taking advantage
of the available single-cell reference generated from different studies, Dong et al. (2020) proposed
SCDC, a bulk RNA-seq data deconvolution algorithm that leverages cell-type-specific expression
profiles from multiple scRNA-seq references.
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Although many methods have been developed for cell type deconvolution, to the best of our knowl-
edge, all existing methods rely on the assumption that the cell-type-specific gene expression ob-
tained from the reference panel can be used to approximate the unobserved cell-type-specific gene
expression in the bulk RNA-seq samples. This assumption is reasonable when the bulk and single-
cell samples are collected from individuals under similar condition, but becomes questionable when
the bulk and single-cell samples are collected from individuals under different conditions. To date,
the majority of the existing single-cell data are sequenced from healthy donors. When referencing
on such data to deconvolve bulk RNA-seq samples generated from diseased subjects, the cell type
proportion estimates can be biased due to potential difference in cell-type-specific gene expression
between healthy and diseased samples. However, none of the existing deconvolution algorithms
is able to address this problem. It is thus desirable to develop a deconvolution method that can
accommodate bulk RNA-seq samples collected from different conditions from the single-cell refer-
ence.
1.3. The scope of this dissertation
Mapping cis-regulatory genetic variants with complex diseases and traits using RNA-seq data alone
is challenging. In this dissertation, taking advantage of RNA-seq and scRNA-seq data, I present
three novel statistical methods that extend the current scope of ASE analysis to learn a compre-
hensive picture of gene regulation mechanism. In Chapter 2, we propose ASEP (Fan et al., 2020),
a generalized linear mixed-effects model based method, to infer gene-level ASE across individu-
als in a population. In addition to detecting gene-level ASE under one condition, ASEP is further
extended to detect gene-based ASE difference between two-condition samples, e.g., pre- versus
post-treatment. Performance of ASEP was evaluated through extensive simulation studies and we
have demonstrated its convincing performance under a variety of scenarios. In addition, by applying
ASEP to human kidney and macrophages RNA-seq datasets, we showed that combining shared
ASE information across SNPs and individuals can lead to easier interpretation and improved power
when detecting ASE. Results from this work can help researchers learn a comprehensive picture
of ASE in the broad population and shed light on the functional roles of GWAS identified genetic
variants.
Solid tissue is composed of diverse cell types with different molecular functions. Accumulating evi-
dence has suggested that gene regulation is often cell-type-specific. Although ASE analysis of the
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bulk tissue samples is useful in evaluating the overall gene regulatory effect across all cells, it may
mask cell-to-cell variation in ASE. To better identify the cellular targets of human diseases, charac-
terizing cell-type-specific allelic expression imbalance (AEI) is necessary. In Chapter 3, we propose
BSCET, a two-step regression-based procedure that integrates bulk and single-cell RNA-seq data
to detect cell-type-specific AEI. In the first step, cell-type deconvolution analysis was employed
to infer cell type compositions in bulk RNA-seq data using scRNA-seq data as the reference. In
the second step, utilizing estimated cell type proportions, we test for cell-type-specific AEI using
allele-specific bulk RNA-seq read counts though a linear regression model. Since the degree of
AEI may vary with disease phenotypes, BSCET is further extended to incorporate clinical factors,
such as disease status, to infer covariates’ effect on cell-type-specific AEI. Through comprehensive
benchmark evaluations, we showed that BSCET was able to detect cell-type-specific AEI using
samples under one condition, as well as differential cell-type-specific AEI between healthy and
diseased samples, and the performance was robust to the choice of scRNA-seq reference. In addi-
tion, BSCET was applied to two pancreatic islets bulk RNA-seq datasets and successfully identified
genes that are related to pancreatic functions and progression of type 2 diabetes. With the promis-
ing performance, we believe BSCET will be a great addition to current methods in elucidating cell
type contributions in human diseases.
Accurately inferring cell type compositions from bulk tissue RNA-seq samples is an important step
towards the understanding of cell-type-specific AEI. All existing methods for cell type proportion
estimation in bulk samples require matched single-cell reference, that is, if the bulk RNA-seq data
are generated from diseased samples, the reference scRNA-seq data should also be obtained
from samples with similar diseased conditions. However, since the majority of existing single-cell
data are generated from healthy individuals, matched single-cell references may not be available.
Deconvolving bulk samples from diseased condition using scRNA-seq data from healthy subjects
as reference can lead to biased cell type proportion estimates. To overcome this limitation, in
Chapter 4, we propose an iterative procedure, MuSiC2, to deconvolve bulk RNA-seq data obtained
under different health conditions from the single-cell reference. Through extensive benchmark eval-
uations and application to pancreatic islets bulk RNA-seq dataset, we have demonstrated that, for
heterogeneous bulk samples, MuSiC2 improved the cell type proportion estimation as compared
to MuSiC (Wang et al., 2019). Given the increasing availability of bulk RNA-seq data generated
under diverse disease conditions, we believe MuSiC2 will be a valuable tool for the identification of
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cellular targets and understanding of the underlying disease mechanism.
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CHAPTER 2
ASEP: GENE-BASED DETECTION OF ALLELE-SPECIFIC EXPRESSION ACROSS
INDIVIDUALS IN A POPULATION BY RNA SEQUENCING
2.1. Introduction
Genome-wide association studies (GWAS) are successful in identifying candidate loci for complex
human diseases and traits (Visscher et al., 2012, 2017). Despite the impressive success for dis-
ease susceptibility loci discovery, few, if any, results from GWAS have led to the delivery of new
therapies (Tam et al., 2019). The association peaks from GWAS typically identify a handful of gene
candidates, but it is often unclear whether these candidates are expressed in relevant tissues and
cell types. Further complicating the picture, we now know that most GWAS signals are probably
the result of regulatory variants that impact gene expression, rather than amino acid changes. Data
on gene expression from tissues and cell types directly involved in disease are critically important
to find causative genes.
A commonly used approach to understand the functional roles of GWAS identified genetic variants
is expression quantitative trait loci (eQTL) analysis (Aguet, Brown, Castel, et al., 2017; Nica and
Dermitzakis, 2013). The rationale is that, a genetic variant, known as an eQTL, influences the
expression level of a gene, and differences in gene expression levels among individuals may lead
to different phenotypes. Studies have found that many GWAS identified single nucleotide poly-
morphisms (SNPs) are significantly enriched for eQTLs, compared to control SNPs matched by
allele frequencies (Nicolae et al., 2010). eQTL analysis identifies both cis- and trans-regulatory
SNPs, in which cis-eQTLs affect gene expression in an allele-specific manner, with implications
on underlying mechanism, whereas trans-eQTLs affect gene expression in an allele independent
manner (Nica and Dermitzakis, 2013). Although eQTL analysis has successfully uncovered func-
tional variant loci that regulate gene expression, typical eQTL analysis only tells local versus distal
association (Dixon et al., 2007; Gilad, Rifkin, and Pritchard, 2008). The lack of explicit information
on cis- versus trans- makes it difficult to directly link to the underlying mechanism, and the require-
ment of a relatively large sample size for eQTL analysis further makes it impractical for studies that
involve difficult-to-collect tissues (Schliekelman, 2008).
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To identify cis-regulated gene expression variation, analysis of allele-specific expression (ASE) is
required. ASE refers to unequal expression between paternal and maternal alleles of a gene in a
diploid individual, driven by cis-regulatory variants located near the gene (Sun and Hu, 2013). The
allelic imbalance of gene expression may explain phenotypic variation and disease pathophysiol-
ogy. Since the two alleles used to measure ASE are expressed in the same cellular environment
and genetic background, they can serve as internal controls and eliminate the influence of trans-
acting genetic and environmental factors. It has been shown that ASE analysis requires 8-fold less
samples than eQTL analysis to reach the same power in detecting cis-regulatory SNPs, and is less
sensitive to SNPs with low minor allele frequencies (MAFs) compared to eQTL analysis (Almlöf
et al., 2012).
To measure ASE, we exploit allelic imbalance by RNA sequencing (RNA-seq), which provides
allele-specific read counts at exonic SNPs distinguished by heterozygous sites (Wang, Gerstein,
and Snyder, 2009). Existing methods for ASE detection report evidence of ASE in single individ-
uals, in which the ASE is quantified for each SNP (e.g., QuASAR (Harvey et al., 2014)), and a
gene-level ASE is obtained by integrating effects across SNPs in the same gene for an individual
(e.g., MBASED (Mayba et al., 2014) and GeneiASE (Edsgärd et al., 2016)). However, evidence of
ASE is often shared across individuals. Failure to accommodate such shared information not only
loses power, but also makes it difficult to interpret results across individuals. It is desirable to have
a method that simultaneously models both multi-SNP and multi-individual information.
ASE detection across individuals, however, is challenging when only RNA-seq data are available,
because the data often include individuals that are either heterozygous or homozygous for the un-
observed cis-regulatory SNPs, leading to heterogeneity in ASE. Such heterogeneity complicates
the analysis because only heterozygous individuals are informative for ASE, whereas those ho-
mozygous individuals have balanced allelic expression. Further, when analyzing multiple SNPs
in the same gene, haplotype phase information is needed to separate the paternal and maternal
alleles. Although it is possible to infer haplotype phase from DNA genotype data, most studies
do not have such data available. Even when phase information is available, cross-individual read
count alignment is still needed when performing cross-individual analysis, which is complicated
as the cis-regulatory SNP is not observed. Figure 2.1 illustrates these analytical challenges in
cross-individual gene-based ASE analysis.
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Figure 2.1: Challenges in cross-individual gene-based ASE analysis
Heterogeneity of the ASE effect exists across individuals in a population. Because the cis-
regulatory SNP (rSNP) is often unobserved, the bulk RNA-seq data include individuals (ID) that
are either heterozygous or homozygous at the rSNP. The mRNA expression levels differ between
two haplotypes only in those heterozygous individuals. Additionally, a gene may have multiple
heterozygous transcribed SNPs (tSNPs). To differentiate paternal and maternal alleles, haplotype
phase information is needed, which is often not available in most studies. Further complicating the
analysis, to aggregate ASE effects across individuals, haplotypes that reside on the same allele of
the unobserved rSNP need to be aligned across individuals.
To properly perform cross-individual gene-based ASE analysis using only the RNA-seq data, we
propose ASEP (Allele-Specific Expression analysis in a Population), a generalized linear mixed-
effects model based method with subject-specific random effect to account for correlation of multi-
ple SNPs within the same gene. ASEP is able to detect gene-level ASE under one condition and
differential ASE between two conditions (e.g., pre- versus post-treatment). Through extensive simu-
lations and analyses of real RNA-seq datasets from human transcriptomic studies, we demonstrate
that combining shared ASE information across SNPs and individuals leads to easier interpretation
and improved power in identifying genes with ASE. Results from our analysis shed light on the
functional roles of GWAS identified genetic variants.
2.2. Material and Methods
2.2.1. Methods overview
The primary goal of ASEP is to perform gene-based ASE analysis across individuals using only
the RNA-seq data. However, the population includes individuals that are either heterozygous or
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homozygous for the unobserved cis-regulatory SNP, and ASE is present only in those heterozygous
individuals. To account for such heterogeneity and simultaneously aggregate multi-individual and
multi-SNP information, we develop ASEP, a generalized linear mixed-effects model based method,
in which the subject-specific random effect is used to account for correlation of multiple SNPs within
the same gene, and sample heterogeneity is modeled by a two-component mixture distribution. Our
method can be applied to detect gene-level ASE under one condition and differential ASE between
two conditions across individuals in a population.
ASEP utilizes allele-specific read counts across transcribed SNPs of a given gene obtained from
RNA-seq. For a given gene g, let rSNP be its unobserved cis-regulatory SNP with alleles R and
r, where we assume the R allele leads to increased expression level of the residing haplotype as
compared to the r allele. The haplotype with higher expression is denoted as the major haplotype,
and the alleles on this haplotype are referred as the major alleles. For individuals homozygous or
heterozygous at the rSNP, we denote them as ’Hom’ or ’Het’, respectively. Let tSNP be an observed
transcribed SNP within the gene of interest detected from the RNA-seq data. Individuals that are
homozygous for the tSNPs are excluded from analysis since they do not provide information on
allelic expression.
When haplotypes are inferred and properly aligned with the unobserved rSNP alleles across in-
dividuals, for one condition ASE analysis, we detect evidence of ASE by testing the existence
of a mixture distribution within the samples, i.e., group-level ASE difference between ’Hom’ and
’Het’ samples. For paired two-condition analysis, we test for the difference of ASE between two
conditions for the ’Het’ individuals. However, RNA-seq data alone do not provide information on
haplotype phase or rSNP. To address these issues, we adopt a pseudo phasing procedure origi-
nally proposed by MBASED (Mayba et al., 2014), which is a ’majority voting’ procedure based on
allele-specific read counts, to infer the major haplotype for each individual.
2.2.2. Detection of ASE under one condition
We assume that only RNA-seq data are available for ASE analysis. For individual i at a transcribed
tSNP j of gene g, let Xij be the read count for the reference allele in the genome, Yij be the total
read count at the SNP, and Mij be the read count for the corresponding allele that resides on the
major haplotype. Mij is assumed to follow a binominal distribution, Binomial(Yij , Pi), where Pi is
the ASE level, representing the underlying transcript frequency of the major haplotype for individual
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i. When there is no gene-level ASE, Pi = 0.5, and Pi > 0.5, otherwise. The allele-specific read
counts of the major haplotypes are then aligned across all individuals. To account for correlations
across multiple tSNPs within the gene, we employ a generalized linear mixed-effects model:
logit(Pi) =  i
where the random effect,  i, represents the individual-specific true underlying transcript frequency
of the major haplotype on a logit scale, and is assumed to follow some unknown distribution denoted
as g( i).
The likelihood of the above model can be written as:
L = ⇧i⇧jf(Mij , Yij , Pi) = ⇧i
Z
⇧jf(Mij , Yij | i)g( i)d i
where f(·) represents the probability density function of a binomial distribution. However, the inte-
gral does not have a closed form because g( i) is unknown. We approximate it by a finite mixture
over two mass points µ1, µ2 with probabilities ⇡, 1 ⇡, respectively, since ’Hom’ and ’Het’ individuals
are expected to have different ASE levels under the alternative hypothesis (i.e., existence of ASE).
The likelihood can then be written as:
L = ⇧i [⇡⇧jf(Mij , Yij |µ1) + (1  ⇡)⇧jf(Mij , Yij |µ2)] (2.1)
Here, µ1 and µ2 indicate the population-level major allele transcript frequency of individuals that are
heterozygous and homozygous for the unobserved rSNP, respectively. Based on our assumption,
µ1, which represents the gene-level ASE effect, will deviate from 0, i.e., logit(0.5), whereas µ2,
which represents the situation of no ASE, will be around 0. To avoid imposing any prior distributional
assumptions on the random effect, parameters are estimated using the non-parametric maximum
likelihood estimation (NPML) approach, an Expectation-Maximization based method developed by
Murray Aitkin (Aitkin, 1999; Einbeck, Darnell, and Hinde, 2018).
To detect gene-level ASE in the population, we test the following hypothesis:
H0 : µ1 = µ2 vs H1 : µ1 6= µ2
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We do not test H0 : µ1 = 0 because we prefer to use individuals who are homozygous at the
rSNP as an internal control to reduce excessive false positive results due to errors from haplotype
phasing and across individual alignment. We employed the likelihood ratio test statistic LRT =
 2(logLH0   logLH1), where the likelihood under H1, LH1 , is calculated using equation 2.1, and
the likelihood under H0, LH0 , is obtained by fitting a standard generalized linear mixed-effects
model assuming a common mean µ for the random effect  i (Bates et al., 2015). Since the null
distribution of LRT does not follow standard  2 distribution, we assess the statistical significance
of the LRT through a resampling-based procedure. Specifically, for each individual i at tSNP j,
we randomly sample Mij from Binomial(Yij , 0.5), and calculate the corresponding LRTn using the




In the above framework, we have assumed the haplotype phase is known and the major allele can
be inferred. However, in real studies, the haplotype phase is often unknown and the observed data
offer little or no information of which allele is the major allele. In the absence of DNA genotype data,
with only the Xij and Yij of the tSNP, it is challenging to infer which alleles at different SNPs reside
on the same haplotype. Even when haplotype phase is known, lacking information of the rSNP
makes it difficult to align read counts across individuals as we do not know which allele resides
on the same haplotype with the R allele. To overcome these challenges, we adapted a pseudo
phasing procedure originally employed by MBASED (Mayba et al., 2014). This procedure uses a
‘majority voting’ approach based on observed read counts. For each individual, when the haplotype
phase information is known, we assign the haplotype with larger total reads, obtained by summing
up read counts across all SNPs on the same haplotype, as the major haplotype. When haplotype
phase is unknown, we assign the allele with larger read counts of each SNP to the major haplotype,
and alleles on the inferred major haplotype are treated as major alleles.
2.2.3. Detection of differential ASE between two conditions
The previously described ASE detection procedure for one condition can be naturally extended to
detect gene-level ASE difference between two conditions (e.g., conditions A and B) using paired
RNA-seq data, where the same individual is sequenced under both conditions. Similar to the







reference allele read count, total read depth and major allele read count accordingly for individual
i under condition c. M c
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true underlying transcript frequency of the major haplotype. After aligning major alleles across










0, if sample i is from condition A
1, if sample i is from condition B
the model can be modified as the following:
logit(P c
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where the random intercept,  i, represents PAi , the individual-specific true underlying transcript fre-
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and Zi are assumed to jointly follow some unknown distribution denoted as g( i, Zi).

























where f(·) represents the probability density function of the binomial distribution. Similar to one





























Here µ1 and µ2 represent the population-level transcript frequency of the major haplotype under
condition A,  1 and  2 represent the difference in the transcript frequency between two conditions,
for ’Het’ and ’Hom’ individuals, respectively. Similarly, the parameters are estimated through the
NPML approach (Aitkin, 1999; Einbeck, Darnell, and Hinde, 2018).
To test gene-level ASE difference between two conditions with the ’Hom’ individuals as an internal
control, we consider the following hypothesis:
H0 :  1 =  2 vs H1 :  1 6=  2
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Same as one condition analysis, the haplotype phase and major haplotype information are often
unknown in real studies when only RNA-seq data are available. Therefore, we employ the pseudo
phasing procedure to determine the major haplotype and align them across individuals (Mayba et
al., 2014). To ensure that the major haplotypes are identical for the same individual under different
conditions, we choose one condition as the ’reference’, obtain its phasing information, and phase
the data from the other condition accordingly. To improve phasing accuracy, following MBASED
(Mayba et al., 2014), the condition with larger ASE effect is used as the ’reference’.
Again, we consider the likelihood ratio test with LRT =  2(logLH0   logLH1) as the test statistic.
Under H1, the observed data likelihood, LH1 , can be approximated using equation 2.2. Under H0,
there is no ASE difference between the two conditions and the random slope Zi = 0. Therefore,
the model reduces to the one condition model and the likelihood, LH0 , can be approximated using
equation 2.1. We assess the significance of the LRT by resampling. To obtain the null distribution
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the individual-specific estimate of the ASE level assuming no ASE difference between the two
conditions. A two-step procedure is employed to obtain p̂i0. First, for individual i, we combine data
















Because we perform pseudo alignment on the RNA-seq data based on a ’reference’ condition, after
the ’majority voting’, for ’Hom’ individuals, p̂i, as the pooled major allele frequency, will always be
larger than 0.5, which violates the assumption of no ASE effect under both conditions. To make the
resampled data represent the null, as a second step, p̂i0 is obtained through a weighted sum as the
following:
p̂i0 = 0.5⇥ ⇡̂i,Hom + p̂i ⇥ ⇡̂i,Het
where ⇡̂i,Hom and ⇡̂i,Het are the estimated posterior probabilities that individual i belongs to the
’Hom’ and ’Het’ group, respectively. If the individual is estimated as ’Hom’ individual with high
probability, i.e., ⇡̂i,Hom is large, this mechanism will down weight p̂i and make p̂i0 to be close to
0.5. If the individual is estimated as ’Het’ individual with high probability, p̂i0 will borrow most of
the information from p̂i and take a value similar as in the pooled sample. Based on the resampled
data, LRTn can be obtained accordingly. This procedure is repeated Nsim times, and the p-value
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is calculated as #(LRTn LRT )
Nsim
.
ASEP is implemented as an R package and is freely available on Github (https://github.com/
Jiaxin-Fan/ASEP), with detailed tutorial and examples provided.
2.2.4. Simulation framework
Without loss of generality, we consider one gene only. To evaluate the performance of ASEP across
a wide range of scenarios, we simulated RNA-seq data for N individuals (20 or 50), each with
nSNP number of tSNPs (2, 4 or 6). For each individual, we generated the data with a pre-specified
minor allele frequency (MAF) of the rSNP (0.1, 0.3 or 0.5), and assigned ’Hom’ or ’Het’ based on
the genotype of the rSNP. The haplo-genotype data were simulated assuming Hardy– Weinberg
equilibrium (HWE) with assigned haplotype frequencies such that, for each tSNP, MAF=0.3 with
the linkage disequilibrium (LD) coefficient between pairs of tSNPs set at 0.8.
Simulation scheme for ASE detection under one condition. The read count for the major allele
of each tSNP was sampled from Binomial(Yij , 0.5) for ‘Hom’ individuals and from Binomial(Yij , Pi)
for ’Het’ individuals across all simulations. For simplicity, we assume Yij = Y for all individuals
across all tSNPs, where Y takes two possible values, 50 or 100. For ’Het’ individuals, when evalu-
ating the type I error rate, we set Pi = 0.5 under both phase known and unknown scenarios. When
evaluating power, to account for subject-specific random variation in ASE levels, Pi, on the logit
scale, was simulated from Normal(logit(P ), 0.032), where P is the pre-specified ASE effect in the
population. We set P = 0.6 under both phase known and unknown situations.
Simulation scheme for differential ASE detection between two conditions. Similar to one
condition analysis, for ’Hom’ individuals, the major allele read count for each tSNP was simulated
from Binomial(Y c
ij
, 0.5) for both conditions across all evaluations. For ’Het’ individuals, the major
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scale, were sampled from Normal(logit(PA), 0.032) and Normal(logit(PB), 0.032), respectively,
where PA and PB are the pre-specified condition-specific ASE effect in the population for condition
A and condition B. When haplotype phase is known, we set PA
i






= 0.625 and PB
i
= 0.7, otherwise. Condition B was used as the ’reference’ for pseudo-phasing
given its stronger ASE effect.
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2.2.5. Human macrophage differentiation and polarization and RNA sequencing
All of the protocols for this study were approved by the Human Subjects Research Institutional
Review Board at the University of Pennsylvania and Columbia University Irving Medical Center.
Peripheral blood mononuclear cell (PBMC) collected using BD VACUTAINER R  Mononuclear Cell
Preparation Tube were cultured in macrophage culture media, 20% FBS in RPMI 1640 media with
100 ng/ml human macrophage colony-stimulating factor (M-CSF), for 7 days on BD PrimariaTM
tissue culture plate to induce macrophage differentiation (Zhang et al., 2017, 2015). Polarization
was obtained in the presence of M-CSF by 18-20 hour incubation with 20 ng/ml interferon-gamma
(IFN- ) and 100 ng/ml lipopolysaccharide (LPS) for M1-like polarization (Zhang et al., 2017, 2015).
RNA samples of M0 and M1 macrophages were extracted using All Prep DNA/RNA/miRNA Univer-
sal Kit (Qiagen, Valencia, CA) by batches and the samples were randomly assigned to each batch
(Zhang et al., 2017, 2015). The RNA quality and quantity were determined by Agilent 2100 Bioan-
alyzer (Median RIN = 7.9, n = 96 samples from 48 subjects). With a minimum of 300 ng input RNA,
libraries were prepared using the TruSeq RNA Sample Preparation Kit (Illumina, San Diego, CA),
followed by 101 bp 60M paired-end sequencing on an Illumina’s HiSeq 4000 at Columbia Genome
Center.
2.3. Results
2.3.1. Detecting ASE under one condition
We evaluated the performance of ASEP to detect gene-level ASE as a function of the number of
individuals (N ), the number of tSNPs (nSNP), sequencing depth (Y ), and pre-specified minor al-
lele frequency (MAF) of the unobserved rSNP. When haplotype phase among tSNPs was known,
our simulations showed that type I error rate of ASEP was controlled at the 1% level under all
scenarios we investigated. As expected, the power increased as the number of individuals, se-
quencing depth or the number of heterozygous tSNPs increased. Among these three factors, the
sequencing depth and the number of tSNPs were more influential as compared to the sample size.
With high sequencing depth and more tSNPs, our method had sufficient power to detect an ASE
effect of 0.6. Further, increasing the proportion of ’Het’ individuals in the sample, determined by
the MAF of the unobserved rSNP, improved the power under all scenarios considered. The model
performed similarly when MAF=0.3 or 0.5, and outperformed the model when MAF=0.1 with other
factors held constant. This is expected since only 18% of the individuals were heterozygous at the
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rSNP when MAF=0.1 under HWE, whereas more than 40% of the individuals were heterozygous
when MAF=0.3 or 0.5, leading to a much larger effective sample size in ASE detection. However,
when the sequencing depth, the number of tSNPs and the MAF of the rSNP were all at low level,
increasing sample size resulted in decreased power. This is likely due to higher uncertainty when
aligning haplotypes across multiple individuals with increased sample size but with less information
on allelic read counts (Figure 2.2A and Figure S2.1A).
Figure 2.2: Simulation results for one-condition analysis
Type I error rate (left) and power (right) evaluated as a function of the number of individuals (N ),
sequencing depth (Y ), number of heterozygous transcribed SNPs (nSNP) and MAF of the cis-
regulatory SNP. For each scenario, the type I error rate was examined with 10,000 simulations, and
the power with 1,000 simulations at significance level ↵ = 0.01. Performance of ASEP (A) when
haplotype phase is known and (B) when haplotype phase is unknown with the population-level ASE
equals 0.6 for power evaluation.
Next, we examined the performance of ASEP when haplotype phase was unknown under similar
scenarios. The type I error rate of ASEP was still well controlled at the 1% level across all scenarios.
The power increased as the sequencing depth or the number of tSNPs increased, with the read
depth having higher impact on power as compared to the number of tSNPs. Notably, we observed
a dramatic power increase as the read depth increased when there were only a few tSNPs in
the gene. Increasing sample size only improved the power when at least two of the three above-
mentioned factors, sequencing depth, number of tSNPs and MAF, were at moderate to high level.
With low level of sequencing depth and MAF of the rSNP, we observed that the power decreased
slightly when the sample size increased. This is because we assigned alleles with larger read
counts to the major haplotype, thus the estimated ASE level for the ’Hom’ group deviated more
from 0.5 when the number of ’Hom’ individuals increased with smaller MAF. This led to smaller
ASE difference between the ’Hom’ and ’Het’ groups and hence decreased the detection power.
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Figure S2.1: Simulation results for one-condition analysis
Type I error rate (left) and power (right) evaluated as a function of the number of individuals (N ),
sequencing depth (Y ), number of heterozygous transcribed SNPs (nSNP) when the MAF of cis-
regulating SNP is 0.5. For each scenario, the type I error rate was examined with 10,000 simula-
tions, and the power with 1,000 simulations at significance level ↵ = 0.01. Performance of ASEP
(A) when haplotype phase is known and (B) when haplotype phase is unknown with the population-
level ASE equals 0.6 for power evaluation.
Similarly, with small number of tSNPs and low level of sequencing depth and MAF, less information
on the SNP level read counts was available, which led to increased phasing errors and resulted in
decreased detection power (Figure 2.2B and Figure S2.1B).
2.3.2. Detecting differential ASE between two conditions
Next, we evaluated the performance of ASEP to detect ASE difference between two conditions.
When haplotype phase information was known, the type I error rate of ASEP was well controlled
at the 1% level across a variety of settings. Similar to the one condition analysis, when MAF of
the rSNP was fixed, the power increased as the number of individuals, the sequencing depth or
the number of tSNPs increased. Among these three factors, the sequencing depth, followed by the
number of tSNPs and the sample size, had the largest impact on power. Moreover, a specific factor
increased the power more when accompanied by the increase of either of the other two factors.
Further, increasing MAF of the rSNP also improved the power to detect differential ASE between
two conditions. With MAF=0.3, when any two of the three factors were at high level, ASEP had an
adequate power to detect a, as small as, 0.05 ASE difference between two conditions (Figure 2.3A
and Figure S2.2A).
When the haplotype phase was unknown, the type I error rate was still under control at the 1% level
across all scenarios. For power evaluation, we set the ASE difference between two conditions to
0.075 to achieve an adequate power. Overall, the detection power followed similar pattern as what
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Figure 2.3: Simulation results for two-condition analysis
Type I error rate (left) and power (right) evaluated as a function of the number of individuals (N ),
sequencing depth (Y ), number of heterozygous transcribed SNPs (nSNP) and MAF of the cis-
regulatory SNP. For each scenario, the type I error rate was examined with 10,000 simulations, and
the power with 1,000 simulations at significance level ↵ = 0.01. (A) Performance of ASEP when
haplotype phase is known. For power evaluation, the population-level ASE takes values of 0.7 and
0.65 for the two conditions. (B) Performance of ASEP when haplotype phase is unknown. For
power evaluation, the population-level ASE takes value of 0.7 and 0.625 for the two conditions.
Figure S2.2: Simulation results for two-condition analysis
Type I error rate (left) and power (right) evaluated as a function of the number of individuals (N ),
sequencing depth (Y ), number of heterozygous transcribed SNPs (nSNP) when the MAF of cis-
regulating SNP is 0.5. For each scenario, the type I error rate was examined with 10,000 simula-
tions, and the power with 1,000 simulations at significance level ↵ = 0.01. (A) Performance of ASEP
when haplotype phase is known. For power evaluation, the population-level ASE takes values of
0.7 and 0.65 for the two conditions. (B) Performance of ASEP when haplotype phase is unknown.
For power evaluation, the population-level ASE takes value of 0.7 and 0.625 for the two conditions.
we observed under phase known scenarios. The power increased as the sequencing depth, the
sample size or the number of tSNPs increased, with the sequencing depth being the most influential
factor among the three as it led to much higher power improvement when the other two factors were
fixed. Increasing the number of ’Het’ individuals also dramatically improved the power. With MAF
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of 0.3, ASEP had sufficient power to detect a 0.075 ASE difference between two conditions when
any two of the three above-mentioned factors were at high level (Figure 2.3B and Figure S2.2B).
2.3.3. Application to a human kidney RNA-seq dataset
We applied ASEP to a human kidney RNA-seq dataset generated from an eQTL study by Qiu
et al. (Qiu et al., 2018), which includes 121 tubule compartment samples. Details of sample
characteristics, RNA-seq data processing and read mapping were described in the original paper
(Qiu et al., 2018). Allele-specific read counts for SNPs in exonic regions were obtained using WASP
(Van et al., 2015), which is robust to mapping bias in the presence of SNPs. For each tSNP, an
individual was filtered out if the minor allele count was less than 5, or the total read count was
less than 20, or the minor allele count was less than 5% of the total read count. In addition, we
only analyzed genes that were expressed in three or more individuals in order to have enough
information for parameter estimation.
In total, we analyzed 6,540 genes and detected 304 genes with significant ASE effect after FDR
multiple testing adjustment. To validate our findings, we first compared our results with eGenes
identified using the same kidney RNA-seq dataset by Qiu et al. (2018). Here an eGene refers
to a gene with cis-eQTLs at 5% FDR, where a cis-eQTL is defined as an eQTL located within 1
megabase (Mb) from the transcription start site of the gene (Ko et al., 2017). 179 (59%) of our ASE
genes were also detected as eGenes by Qiu et al. (2018). We further compared the 304 genes
with another eQTL study performed on a different human kidney cortex RNA-seq dataset of 96
samples (Ko et al., 2017), and found that 97 (32%) of our ASE genes were detected as eGenes
in their analyses, among which 85 were also detected as eGenes by Qiu et al. (2018). Among
genes detected as eGenes by both eQTL studies, GSTM3 showed strong evidence of ASE (FDR
adjusted P < 0.0003). It has been reported that GSTM3 may function as a tumor suppressor in
renal cell carcinoma (Tan et al., 2013). Figure 2.4 shows the estimated SNP-level ASE, i.e., the
proportion of major allele read count relative to the total count of both alleles of each SNP, for each
individual, sorted by their median of estimated ASE levels among heterozygous individuals for the
analyzed tSNPs in the gene. We observed that about one-third of the individuals have estimated
ASE level below 0.6, which presumably are individuals that are homozygous for the unobserved
cis-regulatory SNP, whereas the rest of the individuals showed strong ASE effect. The reason that
the estimated ASE level was greater than 0.5 is due to the ’majority voting’ phasing procedure used
to assign major alleles across SNPs. By aggregating information across individuals, ASEP was
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able to detect a significant ASE signal for this gene (Figure 2.4A).
Figure 2.4: SNP-level ASE for selected ASE genes in the human kidney RNA-seq dataset
We selected three genes, GSTM3 (A), APOC3 (B) and PGAP3 (C), to show their estimated SNP-
level ASE for each SNP and individual. The ASE level was estimated as the major allele proportion,
i.e., the proportion of major allele read count relative to the total count of both alleles of each SNP,
in each sample after haplotype phase alignment. The individuals were sorted by the median ASE
level across all transcribed SNPs in each individual.
We also detected significant ASE in APOC3 (FDR adjusted P = 0.0003). APOC3 is known to
encode protein apolipoprotein C-III, which is highly associated with hypertriglyceridemia and its
altered metabolism may lead to dyslipidemia in chronic kidney disease (CKD) (Ooi et al., 2011).
The RNA-seq data suggest that even though each individual only has a few transcribed SNPs in
this gene, with consistent signals across individuals, ASEP was able to aggregate ASE information
across individuals to facilitate the detection of a population-level ASE effect (Figure 2.4B).
An additional example is PGAP3, which showed strong evidence of ASE by ASEP (FDR adjusted
P < 0.0003). PGAP3 encodes the glycosylphosphatidylinositol (GPI)-specific phospholipase that
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is crucial for protein sorting and trafficking (Howard et al., 2014). A previous study has shown
that aged PGAP3 knockout mice developed the phenotype such as enlarged renal glomeruli with
deposition of immune complexes and matrix expansion (Wang et al., 2013). In this dataset, we
observed that many individuals showed small ASE effect at a few transcribed SNPs. However, by
leveraging information across multiple SNPs and individuals, ASEP was able to uncover the ASE
signal shared across individuals (Figure 2.4C).
Although 113 ASEP detected ASE genes (37%) were not identified as eGenes in either of the two
eQTL studies, many of these genes are related to kidney functions, especially with chronic kidney
disease (CKD). For example, SOD3 (FDR adjusted P < 0.0003) is an antioxidant highly expressed
in normal kidneys and is protective in CKD progression (Tan et al., 2015). SPSB1 (FDR adjusted
P < 0.0003) has been found as a novel regulator of the transforming growth factor-  (TGF- )
signaling pathway (Liu et al., 2015), which mediates fibrosis and plays an important role in CKD
(Sureshbabu, Muhsin, and Choi, 2016). Changes in CYP24A1 (FDR adjusted P < 0.0003) expres-
sion have been shown to be related with dysfunctional vitamin D metabolism. Vitamin D deficiency
may trigger renal osteodystrophy and lead to other complications of renal disease (Petkovich and
Jones, 2011). PIGR (FDR adjusted P < 0.0003) is expressed in renal tubule epithelial cells and
is related to innate immune system and IL4-mediated signaling events pathways (Stelzer et al.,
2016). APOE (FDR adjusted P = 0.0005) modulates lipoprotein metabolism and is significantly
related with CKD progression (Hsu et al., 2005) (Figure S2.3).
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Figure S2.3: SNP-level ASE for selected ASE genes in the human kidney RNA-seq dataset
We selected six genes, SOD3 (A), SPSB1 (B), CYP24A1 (C), PIGR (D), LBH (E) and APOE (F),
to show their estimated SNP-level ASE across SNPs and individuals. The estimated ASE was
obtained by calculating the major allele proportion in the kidney sample after haplotype phase
alignment. The individuals were sorted by the median ASE across all SNPs.
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2.3.4. Application to a human macrophage RNA-seq dataset
Next, we applied ASEP to a paired macrophage RNA-seq dataset generated from 48 healthy in-
dividuals (Table 2.1). Human peripheral blood mononuclear cell (PBMC) can be cultured and dif-
ferentiated to macrophages, and polarized in vitro to functionally and molecularly distinct M1-like
inflammatory macrophages by IFN-  and Lipopolysaccharide (LPS), an important and widely-used
experimental model to study macrophage biology in homeostasis and diseases (Russell, Huang,
and VanderVen, 2019; Wynn and Vannella, 2016). M0 and M1 macrophages from each individual
were subject to 2⇥101 bp paired-end RNA-seq. Reads were aligned to human genome hg19 using
STAR 2.6.0a (Dobin et al., 2013). Reads from each pair were required to map to the same chro-
mosome with distance < 500, 000 bp. Only uniquely mapped reads were retained for downstream
analysis. The RNA-seq data were processed using WASP (Van et al., 2015) to remove possible
mapping bias and extract allele-specific read counts.
Male Female
Sample number (N) 24 24
Age (median,range) 35(22-51) 27(21-50)
Race Caucasian Caucasian
Table 2.1: Subject demographics of the macrophage samples
We first applied ASEP for one condition analysis to M0 and M1 macrophage samples separately
to detect ASE genes under each condition. Similar filtering criteria to the human kidney RNA-seq
analysis were applied. In total, we analyzed 5,961 genes for the M0 and 5,465 genes for the M1
macrophage samples, with 4,783 genes in both. We identified 2,503 genes with significant ASE
(P < 0.05) in M0 and 2,580 genes in M1. Among these genes, 1,223 were detected only in M0,
with 408 of them not expressed in M1, and 1,300 genes detected only in M1, with 334 of them not
expressed in M0. Additionally, 1,280 genes showed evidence of ASE under both conditions. After
multiple testing adjustment with FDR, 2,402 genes remained significant (FDR adjusted P < 0.05)
in M0 and 2,489 genes in M1, and 1,223 genes were found to have ASE under both conditions
(Figure 2.5A).
To validate our findings, we first compared our results to an eQTL study based on monocytes from
134 healthy males (Kim-Hellmuth et al., 2017). The monocytes were stimulated with three proto-
typical microbial ligands, LPS was used to activate Toll-like receptor 4 (TLR4), muramyl-dipeptide
(MDP) to stimulate Nucleotide-binding oligomerization domain-containing protein 2 (NOD2), and
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Figure 2.5: Genes analyzed for ASE and differential ASE analysis in the macrophage RNA-seq
dataset
(A) Total number of genes analyzed, and number of significant ASE genes in M0 (pink) and M1
(green) macrophages obtained from one-condition analysis. Solid circles indicate the nominal sig-
nificant (left) and FDR-adjusted significant (right) ASE genes detected under each condition. (B)
Total number of genes analyzed for two-condition analysis. Genes were selected from significant
(nominal) ASE genes for M0 (pink) and M1 (green) macrophages that expressed under both con-
ditions. Genes with less than three matched reads, i.e., the tSNP has read counts for both M0
and M1 macrophages of the same individual, were further excluded from the analysis. Solid circle
indicates the FDR-adjusted significant differential ASE genes detected between M0 and M1.
5’-triphosphate RNA to activate retinoic acid-inducible gene I (RIG-I). RNAs from these samples
were sequenced at baseline, 90 minutes and 6 hours after stimulation. We found 460 (19%) of the
FDR significant ASE genes for M0 macrophages overlapped with the eGenes identified at the base-
line, and 493 (20%) of the ASE genes for M1 macrophages overlapped with the eGenes identified
at either 90 minutes or 6 hours using one of the three microbial ligands as the stimuli. To exam-
ine if the percent overlapping eGenes (pobserved) is more than expected by chance, we performed
resampling based enrichment analysis. For the 2,402 ASE genes detected for M0, we randomly
sampled 2,402 genes from the remaining 3,559 genes that did not show evidence of ASE, and
recorded the percentage of genes (presampled) overlapping with eGenes in the monocyte eQTL
study (Kim-Hellmuth et al., 2017). We repeated this resampling procedure 10,000 times and the
eGene enrichment p-value was calculated as #(presampled pobserved)10,000 . Similar analysis was performed
for ASE genes detected for M1. Both M0 and M1 ASE genes have enrichment p-values less than
0.0001, suggesting the observed overlap with eGenes is more than expected by chance.
Encouraged by these results, we next performed differential ASE analysis between M0 and M1 by
selecting the 2,714 candidate genes that were found to show evidence of ASE (P < 0.05) in M0 or
M1 from the one condition analysis. Since haplotype phase is unknown, to reduce phasing error, for
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each gene, we chose the condition with higher estimated ASE effect as the ’reference’ to phase the
data from the other condition. In total, we detected 826 genes showing evidence of differential ASE
(P < 0.05), with 582 genes still being significant after multiple testing adjustment (FDR adjusted
P < 0.05) (Figure 2.5B). We compared the differential ASE genes with response eQTLs identified
in the monocyte eQTL study, where a response eQTL was defined as an eQTL with different effect
between baseline and stimulated cells (Kim-Hellmuth et al., 2017). We found 15 (3%) of our differ-
ential ASE genes had response eQTLs identified between monocytes at baseline and monocytes
stimulated using at least one of the three microbial ligands sequenced at either 90 minutes or 6
hours: TRABD, AGTRAP, TMEM9, IRF5, AAK1, EIF2AK1, GBP3, GLRX, JUP, MBNL1, MCM7,
MS4A7, PTGER4, SLFN5, TMEM110. For example, IRF5 has been demonstrated to promote
inflammatory macrophage polarization (Krausgruber et al., 2011); GBP3 encodes a protein from
the guanylate-binding protein family that is expressed in response to interferons and other pro-
inflammatory cytokines and mediates innate immune responses against intracellular pathogens
(Praefcke, 2018); SLFN5 belongs to the schlafen family and plays an important role in the regula-
tion of human T cell quiescence (Puck et al., 2015).
Since macrophages are important regulators and promoters of many cardiovascular disease pro-
grams, we further examined whether the 582 genes showing significant differential ASE overlap
with findings from GWAS for cardiovascular disease (CVD), coronary artery disease (CAD) and
acute coronary syndrome (ACS) (Lehrke et al., 2007). Among these 582 genes, 323 (56%) over-
lapped with loci that reached GWAS significance (P < 5⇥ 10 8). The differential ASE genes were
marginally enriched for GWAS findings of selected traits as compared to those non-differential ASE
genes (P = 0.078). For example, CCL3 (FDR adjusted P < 0.00002) encodes the macrophage
inflammatory protein-1↵ that is known as a macrophage-derived inflammatory mediator and plays
a well-known role in inflammatory responses (Baba and Mukaida, 2014). Figure 2.6 shows the
estimated SNP-level ASE difference for each individual, i.e., the difference in major allele propor-
tion of each SNP after haplotype phasing between M1 and M0 for each individual. After sorting
individuals by their median of estimated ASE difference across all heterozygous transcribed SNPs,
we observed that, the majority individuals have negative ASE difference with a few having positive
ASE difference, which might be due to potential phasing error. About one-third of the individuals
have median ASE difference around zero, and these individuals are presumably homozygous for
the unobserved rSNP. However, since more individuals have negative ASE difference, ASEP was
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able to detect evidence of differential ASE at the population level by aggregating information across
individuals and multiple transcribed SNPs within the gene (Figure 2.6A).
We also detected differential ASE in CASP8 (FDR adjusted P = 0.0003) in the macrophage data.
A previous study has shown that loss of CASP8 expression in macrophages led to onset of a
mild systemic inflammatory disease (Cuda et al., 2015). CASP8 can control the response to TLR
activation and macrophage polarization in a RIPK-dependent manner. Our RNA-seq data suggest
that even though each SNP may have small effect, by aggregating information across SNPs and
individuals, ASEP was able to uncover the consistent differential ASE signal between conditions in
the population (Figure 2.6B).
Additionally, we detected differential ASE for IL1RN (FDR adjusted P < 0.00002), which encodes
protein interleukin-1 receptor antagonist (IL-1RA) that modulates a variety of interleukin 1 related
immune and inflammatory responses (Arend et al., 1998; Stelzer et al., 2016). Although each in-
dividual only has a few transcribed SNPs in this gene, by accumulating evidence across multiple
individuals, we were able to detect a consistent signal of differential ASE (Figure 2.6C). Further,
we detected differential ASE in ABHD16A (FDR adjusted P < 0.00002). A study has shown that
ABHD16A dynamically regulates the metabolism of lysophosphatidylserines (lyso-PS), a class of
signaling lipids that regulate (neuro)immunological processes (Kamat et al., 2015). Although het-
erozygous sites in ABHD16A varied across individuals and most of them are heterozygous for only
one transcribed SNP in this gene, for each SNP the ASE effect was consistently larger in M1 than
in M0. By aggregating information across multiple SNPs and individuals, ASEP was able to detect
a population-level differential ASE effect (Figure 2.6D).
Other genes that showed significant differential ASE include those from the cluster of differentiation,
e.g., CD226 (FDR adjusted P < 0.00002), CD68 (FDR adjusted P < 0.00002) and CD44 (FDR
adjusted P = 0.004)), RCAN1 (FDR adjusted P ¡ 0.00002), TSPO (FDR adjusted P < 0.00002),
AKT1 (FDR adjusted P = 0.00008), and PIEZO1 (FDR adjusted P = 0.001).
Although 259 of the differential ASE genes did not overlap with GWAS findings, some of them
may play a relevant role in inflammation. For example, MAPK14 (FDR adjusted P = 0.0009) (Fig-
ure 2.6E), is involved in the production of inflammatory mediators, and play an essential role in
mediating cellular responses to injurious stress and immune signaling (Kim et al., 2008; Yang et al.,
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Figure 2.6: SNP-level ASE difference between M0 and M1 macrophage samples for selected
genes showing differential ASE in the macrophage RNA-seq dataset
We selected five genes, CCL3 (A), CASP8 (B), IL1RN (C), ABHD16A (D) and MAPK14 (E), to
show their estimated SNP-level ASE difference for each SNP and individual. The estimated ASE
difference was calculated as the difference in the major allele proportion between M1 and M0 sam-
ples after haplotype phase alignment. The individuals were sorted by the median ASE difference
across all SNPs of each individual.
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2014). Other genes of interest include DDX24 (FDR adjusted P < 0.00002), GRK3 (FDR adjusted
P < 0.00002), GBP2 (FDR adjusted P = 0.00002), EEF2 (FDR adjusted P = 0.00009) and SLFN5
(FDR adjusted P = 0.005), where SLFN5 was also identified as having response eQTL in the
monocyte study (Kim-Hellmuth et al., 2017). For example, DDX24 negatively regulates the RIG-
I-Like Receptors (RLR) pathway and type I IFN production, which may in turn negatively regulate
the innate immune signaling (Ma et al., 2013). A study has shown that GRK3  /  mice exhibit
numerous features of human WHIM syndrome, a rare congenital immune deficiency, indicating its
potential effects on attenuating inflammatory responses. GBP2, similar to GBP3, belongs to the
GBP family, which is mainly induced by IFN-  and may play an important role in defense against
pathogens (Praefcke, 2018). EEF2 has been found to be overexpressed in a wide variety of can-
cers as an antigen that can elicit both humoral and cellular immune responses (Oji et al., 2014)
(Figure S2.4).
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Figure S2.4: SNP-level ASE difference between M0 and M1 macrophage samples for selected
genes showing differential ASE in the macrophage RNA-seq dataset
We selected five genes, DDX24 (A), GRK (B), GBP2 (C), EEF2 (D) and SLFM5 (E), to show their
estimated SNP-level ASE difference across SNPs and individuals. The estimated ASE difference
was obtained by calculating the major allele proportion difference between M1 and M0 samples




ASE detection is an important step towards the understanding of genetic polymorphisms on gene
expression variation. However, existing ASE detection methods mainly focus on individual-based
ASE effect. To better utilize shared ASE information across individuals, we proposed ASEP, a
novel method that can detect allelic imbalance in gene expression across individuals under one
condition, and differential ASE between two conditions using only RNA-seq data. The main ad-
vantage of ASEP lies in its ability to leverage information across multiple individuals and SNPs
within the same gene. Existing methods, such as MBASED (Mayba et al., 2014), detect ASE effect
through individual-based analysis, which makes it difficult to aggregate information across subjects.
GeneiASE (Edsgärd et al., 2016) uses Fisher’s meta-analysis method to combine p-values across
subjects, however, the resulted p-value is driven by extremely small p-values, which may lead to a
significant combined p-value even when ASE is absent in the majority of subjects.
A major challenge for cross-individual ASE analysis based on RNA-seq data alone is due to the
difficulty in differentiating ’Hom’ and ’Het’ individuals as the underlying cis-rSNP is unobserved in
the absence of DNA genotype data. By employing a mixture model, ASEP is able to aggregate
ASE effects contributed by those ’Het’ individuals while accounting for heterogeneity introduced
by those ’Hom’ individuals. As a result, ASEP is not only more powerful, but its results are also
easier to interpret compared to traditional ASE tests that consider one individual at a time. Through
extensive simulations, we showed that ASEP is sensitive in detecting small ASE effect under a
wide range of scenarios. We further demonstrated that the ASE effects uncovered by ASEP are
convincing through the analysis of RNA-seq datasets on human kidney and macrophages.
ASEP can be applied when haplotype phase information in the transcribed SNPs is known or un-
known. When sequencing depth is high, the haplotype phase reconstruction approach employed
by ASEP is able to correctly recover the true major haplotype. For genes with relatively low se-
quencing depth, correct assignment of haplotype phase will increase the power to detect ASE.
Since rSNP is unobserved, paired RNA-seq data are needed for two-condition analysis in order to
correctly phase the haplotypes and align them consistently across samples from both conditions.
If DNA genotype data and phase information are available, then based on alleles of a candidate
regulatory SNP, we not only can differentiate the ‘Het’ individuals but also can easily align ’major’
haplotypes that reside on the same haplotype with the expression-increasing allele across individ-
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uals. This way, our method can be easily modified to detect ASE difference using all available data
or even for unpaired samples, such as case-control study, to detect differential ASE between two
independent groups. ASEP is a regression-based framework for ASE analysis, which is flexible and
can be easily extended to adjust for additional covariates or confounders in the model if necessary.
In summary, we have developed ASEP1, a gene-based ASE detection method by aggregating
information across individuals and SNPs within the same gene. ASEP can detect genes with shared
ASE effect or differential ASE across individuals in a population, which leads to easier interpretation
and improved power as compared to traditional individual-based ASE detection methods. With the
wide application of RNA-seq in biomedical studies, more and more samples of the same tissue from
different individuals become available to study gene-phenotype correlation. There is an urgent need
to learn a comprehensive picture of ASE in the broad population instead of focusing on individual-
level effect. We believe ASEP, which, to the best of our knowledge, is the first method for population-
based ASE detection, will be well-suited for various ASE studies for human diseases.
1This work has been published in PLOS Genetics and is available online through: https://journals.plos.org/
plosgenetics/article?id=10.1371/journal.pgen.1008786 by Fan et al. (2020).
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CHAPTER 3
DETECTING CELL-TYPE-SPECIFIC ALLELIC EXPRESSION IMBALANCE BY
INTEGRATIVE ANALYSIS OF BULK AND SINGLE-CELL RNA SEQUENCING DATA
3.1. Introduction
Allelic expression imbalance (AEI) refers to the phenomenon where the expression between the
paternal and maternal alleles of a gene differs in their magnitude in a diploid individual (Pastinen
and Hudson, 2004). In the presence of cis-regulatory effect, the expression increasing allele at
a cis-regulatory polymorphism can lead to higher expression of one allele compared to the other.
Such allelic imbalance in gene expression may associate with phenotypic variations among individ-
uals and contribute to human disease. Since AEI measures the expression of two alleles expressed
in the same cellular environment, evidence of AEI can rule out the influence of tran-regulatory vari-
ants, and thus is ideal for detecting cis-regulatory effects and pinpointing causal variants for disease
(Sun and Hu, 2013).
Traditionally, allelic expression imbalance (AEI), a.k.a. ASE in previous Chapters, is studied by bulk
RNA-seq in which the allelic expression differences at heterozygous exonic SNPs are characterized
by allele-specific read counts (Edsgärd et al., 2016; Fan et al., 2020; Mayba et al., 2014). However,
solid tissue is typically composed of cells that originate from diverse cell types, and bulk RNA-seq
can only measure the average expression across all cells in a bulk tissue sample. Previous studies
have shown that gene expression is often altered in a cell-type-specific manner, and it is possible
that only certain cell types are responsible for phenotypic changes (Handley et al., 2015; Shen-Orr
et al., 2010). To gain further insight into the cis-regulatory effect, it is necessary to characterize AEI
with cell type resolution.
Recent advances in single-cell RNA sequencing technologies have enabled researchers to charac-
terize individual cells and study gene expression with cell type resolution even for rare cell popula-
tions (Hwang, Lee, and Bang, 2018). However, to study the cell-type-specific effect of AEI across
individuals, full-length transcript sequencing in single cells across a large number of individuals is
needed. Given the current cost of scRNA-seq, it is still cost prohibitive to generate such data. Since
a large amount of bulk RNA-seq data in disease relevant tissues have already been generated in
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previous studies, it is desirable to characterize cell-type-specific AEI using these existing data by
leveraging cell-type information provided by scRNA-seq.
The goal of this project is to develop a two-step regression-based procedure that allows us to inte-
grate Bulk and Single-cell RNA-seq data to detect CEll-Type-specific allelic expression imbalance
(BSCET). First, we perform cell-type deconvolution analysis to infer cell type composition in bulk
RNA-seq data. Second, given estimated cell type proportions in bulk RNA-seq samples, we test
cell-type-specific AEI using allele-specific bulk RNA-seq read counts. Since the degree of AEI may
vary with disease phenotypes, we further extend BSCET to incorporate clinical factors such as dis-
ease status to infer covariate effects on cell-type-specific AEI. Through comprehensive benchmark
evaluations and real data applications to two pancreatic islet bulk RNA-seq datasets, we show that
BSCET is able to detect cell-type-specific AEI and differential cell-type-specific AEI between healthy
and diseased samples, and identify genes that are related to the progression of type 2 diabetes.
3.2. Material and Methods
3.2.1. Methods overview
The primary goal of BSCET is to detect cell-type-specific AEI across individuals using bulk RNA-
seq data. It takes two datasets as input, a bulk RNA-seq dataset, which is used to detect cell-type-
specific AEI, and a scRNA-seq dataset that is used as a reference to infer cell type composition
in the bulk data. After cell type composition for all bulk RNA-seq samples are inferred, for each
transcribed SNP, BSCET then aggregates allele-specific read counts from the bulk RNA-seq data
across individuals to model cell-type-specific expression difference between two alleles by linear
regression, and tests for the evidence of cell-type-specific AEI. For a SNP with cell-type-specific
AEI, it might be of interest to further investigate if its cell-type-specific AEI is affected by any clin-
ical factors. This can be achieved by including covariates in the regression. Specifically, BSCET
models the difference in expression between the two transcribed alleles of the SNP over cell type
composition and includes interactions between cell type composition and the covariate of interest.
By testing the interaction term, BSCET assesses whether this covariate alters the cell-type-specific
AEI in the corresponding cell type. An overview of BSCET is shown in Figure 3.1.
3.2.2. Step 1: Estimating cell type proportions by deconvolution
Since cell type proportions are often unknown in bulk RNA-seq samples, in this step, we aim to
infer cell type proportions in the bulk RNA-seq samples by incorporating cell-type-specific gene
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Figure 3.1: Overview of BSCET
The method contains two steps. (A) First, we employ the deconvolution method, MuSiC (Wang
et al., 2019), to infer the cell type proportion, pk
j
, of the bulk tissue for each individual j of cell
type k by incorporating the cell-type-specific expression information, ✓k
jg
, and cell size factor, Sk
j
,
obtained from scRNA-seq data. (B) Second, at each transcribed SNP (tSNP) site, we align the
tSNP alleles with respect to its reference and alternative alleles, T and t, across individuals, and





estimated cell type composition, pk
j
, through a linear regression model with an intercept term ↵
to capture the information not explained by the selected K cell types, where both mj and Skj are
assumed known. The difference of population-level relative abundance between two transcribed
alleles, ✓k, can therefore be inferred for each cell type. By testing for H0 : ✓k = 0, we can detect
cell-type-specific allelic imbalance across samples.
expression information provided by a scRNA-seq reference. This can be achieved by cell type
deconvolution algorithms such as MuSiC (Wang et al., 2019). Following MuSiC (Wang et al., 2019),
for gene g of individual j, the total bulk-level read count, Xjg, can be written as a weighted sum of













where, for individual j, mj is the total number of cells in the tissue for bulk RNA-seq, pkj is the
proportion of cells from cell type k, Sk
j
is the average cell size of cell type k, and ✓k
jg
is the relative




are often not available, by
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borrowing information from external scRNA-seq reference, they can be approximated by the sample
means, Sk and ✓k
g




(k = 1, . . . ,K), can be inferred through a weighted non-negative least squares regression by
regressing the bulk-level expression across all genes, Xjg (g = 1, . . . , G), on the cell-type-specific
gene expression, Sk✓k
g
(k = 1, . . . ,K). MuSiC (Wang et al., 2019) has shown superior performance
in estimating cell type proportions than popular methods such as CIBERSORT (Newman et al.,
2015).
3.2.3. Step 2: Detecting cell-type-specific AEI
To detect cell-type-specific AEI across individuals in a population, we consider one transcribed
SNP at a time. For ease of notation, we omit index for genes. Let T and t be the two alleles




be the read counts for the T and t alleles,
respectively. Following MuSiC (Wang et al., 2019), the bulk-level read count of each transcribed





































are independent random errors assumed to follow Normal(0, 2), and ✓kT and ✓kt are mean





















k + ✏j (3.1)
where ↵ = ↵T   ↵t represents allelic expression difference not explained by the selected K cell
types, and ✓k = ✓kT   ✓kt represents allelic expression difference between alleles T and t in cell
type k.
We expect the two transcribed alleles to be equally expressed, i.e., ✓k = 0, in the absence of cell-
type-specific AEI, and ✓k 6= 0 otherwise. Therefore, to detect cell-type-specific AEI in the population,
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for cell type k, we test the following hypothesis,
H0 : ✓
k = 0 vs H1 : ✓
k 6= 0
using a t statistic.
Although we can use estimated cell type proportions obtained from MuSiC (Wang et al., 2019) to
approximate pk
j
, mj and Skj are not directly observed. To circumvent this, we use the individual-
specific library size factor obtained from DESeq2 (Love, Huber, and Anders, 2014) as an estimate
for mj . For Skj , we borrow the idea from MuSiC (Wang et al., 2019) and approximate it by Sk,
assuming that cell size of all individuals is equal for a given cell type. Since Sk is a constant across
all individuals, it is considered as a nuisance parameter and not estimated.
3.2.4. Step 2 extension: Association between cell-type-specific AEI and covariates
As a regression-based method, we can readily extend it to assess covariate effects on cell-type-
specific AEI. For illustration purposes, we only consider one covariate, but it is straightforward to
incorporate multiple covariates. Let Vj be the covariate of interest for individual j. We modify


















 ) + ✏j (3.2)
where ✓k is the population-level AEI of the transcribed SNP for cell type k controlling for the covari-
ate; ✓k  is the covariate effect on the cell-type-specific AEI, interpreted as the change in population-
level AEI for cell type k as the covariate increases by 1 unit; ✏j is the random error term and
assumed to follow Normal(0, 2). For example, in a case-control study where the covariate indi-
cates disease status (e.g., coded as 1 for cases), ✓k is the cell-type-specific AEI in controls, and ✓k 
is the difference in the cell-type-specific AEI between cases and controls, a.k.a. cell-type-specific
differential AEI.
In practice we will likely test for the covariate effect on cell-type-specific AEI only if a cell-type-
specific AEI has been detected based on model 3.1. Therefore, in model 3.2, we are interested in
testing whether the cell-type-specific AEI changes with the covariate, i.e., for each cell type k, we
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test the following hypothesis,
H0 : ✓
k
  = 0 vs H1 : ✓
k
  6= 0
using a t statistic.
3.2.5. Benchmark bulk RNA-seq data generation
To evaluate the performance of BSCET, we constructed benchmark bulk RNA-seq data in which
the cell type proportions and AEI levels for each cell type are known. The benchmark data include
60 individuals generated using a publicly available scRNA-seq dataset on human pancreatic islets
from three healthy individuals (Baron et al., 2016). For each individual in the benchmark bulk
RNA-seq data, we generated 5,000 single cells from six selected cell types, including alpha, beta,
delta, ductal, gamma and stellate. The cell type proportions were assumed to follow a Dirichlet
distribution, with mean proportions inferred from the original scRNA-seq data (Baron et al., 2016)
(Figure 3.2A).
Since BSCET analyzes one transcribed SNP at a time, for the benchmark bulk RNA-seq data, we
assumed each gene only has one transcribed SNP. For each cell, we simulated read counts for
11,300 SNPs, corresponding to the number of genes expressed in the original scRNA-seq data.
To better reflect patterns seen in real data, for each cell type, we generated read counts only for
a fraction of cells, with the percentage of expressed cells inferred from the original scRNA-seq
data. Figure 3.2B shows the overall workflow for benchmark dataset generation. Briefly, for each
gene, we obtained the mean cell-type-specific expression across cells from the original scRNA-
seq data. This mean value set the Poisson distribution rate parameter and subject-specific mean
expression was sampled from this Poisson distribution. To generate cell-specific total read count
for each individual, we sampled from another layer of Poisson distribution where the rate parameter
was determined from the previous step. The total read count of each transcribed SNP was then
split into two allele-specific read counts through a binomial distribution with the probability set by
the predefined cell-type-specific AEI for the gene. For cell types without AEI, we set their AEI level
to 0.5 for all genes. For cell types with AEI, we assumed their AEI levels for each gene followed a
truncated gamma distribution with the majority of genes having small to moderate AEI. By summing
up allelic read counts across all cells, we obtained the benchmark bulk-level gene expression data.
We also generated benchmark data that include samples from two conditions (e.g. healthy versus
diseased). This allows us to evaluate the performance of BSCET in detecting covariate effect
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Figure 3.2: Benchmark evaluation data generation scheme
(A) Cell type composition assumed for the artificial bulk RNA-deq data. For each cell type, the solid
line indicates the average cell type proportions across samples, which was inferred from the single-
cell data (Baron et al., 2016). (B) Data generation scheme for obtaining the artificial allele-specific
bulk RNA-seq data. Given gene g, for each cell type k, we first inferred the mean expression level
from the single-cell data (Baron et al., 2016). Based on the sample mean, we next sampled the
subject-specific mean expression through Poisson distribution, and used another layer of Poisson
sampling to obtain the total read count of each cell c. The total expression was then split into two
allele-specific read counts through a binomial distribution with the probability equals to the cell-
type-specific AEI. For each gene g, we generated data only for a single SNP, and the level of AEI
equaled to 0.5 for cell types with no allelic imbalance and was generated from a truncated gamma
distribution for cell types with AEI. The artificial bulk RNA-seq data was obtained by summing up
allelic read counts across all cells.
on cell-type-specific AEI. Using similar data generation scheme as described above, we generated
artificial single-cell and bulk RNA-seq data for 200 individuals, with the ratio of healthy and diseased
being 1:1 or 7:3. For each gene, we assumed only the major cell type, i.e., the cell type with the
highest mean expression among all cell types, had AEI, and 50% of the genes had differential AEI
between healthy and diseased individuals. For genes with cell-type-specific differential AEI, the AEI
level for diseased individuals was assumed to be higher than that of healthy individuals by  AEI ,
which took two possible values, 0.1 and 0.2.




3.3.1. Detection of cell-type-specific AEI when one cell type has AEI
The simulated benchmark bulk RNA-seq data include 60 individuals and the data were generated
with known cell type proportions and cell-type-specific AEI levels. We considered two scenarios:
first, we assumed only the major cell type had AEI; and second, we assumed both the major and
a non-major cell type had AEI. For each gene, the major cell type was selected as the cell type
with the highest mean expression among all cell types, and a non-major cell type was selected
as the one with median mean expression in the scRNA-seq data (Baron et al., 2016), from which
the benchmark bulk RNA-seq data were sampled. Under each scenario, the model performance
was evaluated using both the true and “estimated” cell type proportions, where the “estimated”
proportions were obtained by adding random noise to the true proportions to reflect estimation







(1 + ✏jk), where pkj is the true proportion and the random noise, ✏jk, was sampled from
Normal(0, 0.22). As a comparison, we also analyzed the benchmark data using a traditional bulk
AEI detection method that ignores cell-type-specific effect. In this analysis, the allelic read counts
were modeled using a generalized linear model (GLM) for binomial data with logit link function. The
relative expression of the reference allele over total read counts was modeled across individuals
using an intercept only model, and evidence of AEI was assessed by testing whether the intercept
is significantly different from zero.
We analyzed 11,300 SNPs in total and evaluated the type I error on cell types that did not have
cell-type-specific AEI. Under the first scenario where only the major cell type had AEI, when using
true cell type proportions as input for BSCET, the false positives were under control at the 0.05
significance level (Figure 3.3A). We correctly identified 2,651 SNPs showing cell-type-specific AEI
after false discovery rate (FDR) adjustment for multiple testing. The overall detection power was
higher for alpha, beta, and ductal cells than delta and gamma cells, which was not surprising since
alpha, beta and ductal cells are the common cell types in islets (Lawlor et al., 2017; Wang et al.,
2019). Interestingly, despite the low proportion in bulk tissue, stellate cells had the highest detection
power among all cell types, likely due to its highest expression level among the six cell types in the
scRNA-seq data (Baron et al., 2016). As a comparison, the traditional GLM method for bulk data
analysis detected 2,813 SNPs with AEI, among which 1,662 overlapped with the SNPs detected by
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BSCET. We found that SNPs detected only by the bulk GLM method had a higher expression level
on average (mean reads of 481.7 with interquartile range (IQR) 166.9-583.3) compared to those
detected only by BSCET (mean reads of 144.2 with IQR 55.4-183.3) (Figure 3.4). As the bulk
detection method is sensitive to high read counts, whereas BSCET deconvolves the read counts
into each cell type, it is not surprising that the bulk method is more powerful than BSCET when
sequencing depth is high. However, the goal of BSCET is not to detect more genes than the bulk
GLM method, but rather to elucidate in which cell type the evidence of AEI is present. Nevertheless,
for SNPs with not that high coverage at the bulk level, BSCET correctly detected some of them with
cell-type-specific AEI while the bulk GLM method failed to detect. For most of these SNPs, the
major cell type does not have high cell type proportions, thus the bulk GLM method has limited
detection power as the AEI signals were diluted due to other more common cell types that do not
have AEI.
Figure 3.3: Benchmark evaluation for cell-type-specific AEI detection assuming one cell type with
AEI
We evaluated the performance of BSCET assuming the major cell type for each SNP, i.e., cell type
with the highest mean expression in scRNA-seq data (Baron et al., 2016), had cell-type-specific
AEI using true cell type proportions. (A) Type I error rate and power evaluated at the cell type
resolution under significance level ↵ = 0.05 (dashed line). (B) Detection power separated by the
cell type and true level of AEI. The number above each bar indicates the total number of genes with
cell-type-specific AEI within the category. The solid line indicates the overall power, i.e., across all
cell types, at each level of AEI.
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Figure 3.4: Benchmark comparison of BSCET and bulk GLM method assuming one cell type with
AEI
From the benchmark data assuming one cell type with AEI, we selected SNPs with small to moder-
ate bulk-level AEI, i.e., < 0.6, and plotted their bulk-level mean expression against the AEI, where
the bulk-level AEI was estimated as the reference allele proportion, i.e., the proportion of reference
allele read count relative to the total count of both alleles of each SNP. We colored each SNP ac-
cording to whether it was detected as cell-type-specific AEI by BSCET only (green), AEI by the bulk
detection method only (blue), or by both methods (red). On each margin, using the same color
scale, we used histogram to show the distribution of bulk-level AEI (top) and mean expression level
(right) for the SNPs.
We further evaluated the performance of BSCET at different AEI levels (Figure 3.3B). As expected,
BSCET detected more genes as the true AEI level increased, and the power reached 80% when the
AEI was as large as 0.7. Similarly, the power increased with AEI level for most cell types, except for
alpha cells, which was likely due to the relatively small number of SNPs in the [0.7, 1) AEI category.
Further, at different AEI levels, alpha, beta, ductal and stellate cells had higher detection power in
general than delta and gamma cells, and the difference became smaller as the underlying true AEI
increased. BSCET performed the best in stellate cells when the AEI effect was low to moderate,
indicating that it is able to detect small AEI effect even for rare cell types, as long as the expression
level is relatively high.
Next, we evaluated the performance of BSCET using ”estimated” cell type proportions. Again, the
type I error was well controlled. Among the 11,300 tested SNPs, 2,276 were detected to have
cell-type-specific AEI after FDR adjustment. As expected, the power was slightly lower than that
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when the true cell type composition was used. However, the SNP-level p-values obtained using the
”estimated” proportions were highly correlated with those obtained using the true proportions (R =
0.94, Figure S3.1B). Further, we observed a similar increasing pattern in power over the true AEI
levels as well as similar power differences between cell types, indicating that BSCET is robust to
estimation uncertainty in cell type proportions (Figure S3.1C).
Figure S3.1: Benchmark evaluation for cell-type-specific AEI detection assuming one cell type with
AEI
We evaluated the performance of BSCET when only the major cell type for each SNP had AEI
using “estimated” cell type proportions, where the “estimated” proportions were obtained by adding
random noise to the true proportions. (A) Correlation of true cell type proportions versus the “es-
timated” cell type proportions at cell type level. (B) Scatterplot of cell-type-specific AEI p-values
obtained using true cell type proportions versus those obtained using “estimated” proportions. (C)
Type I error rate and power, separated by the cell type and true AEI level, at significance level
↵ = 0.05 (dashed line). The solid line indicates the overall power across all cell types at each level
of AEI.
3.3.2. Detection of cell-type-specific AEI when two cell types have AEI
We also considered the scenario in which both the major cell type and a non-major cell type had
AEI. Rather than letting all SNPs had AEI for both cell types in the same direction, we assumed
the effect was in opposite directions for 30% of the 11,300 tested SNPs. For these 30% of the
SNPs, the AEI effects in the two cell types would cancel each other out when averaging across all
cells, thus the bulk detection method might fail to detect evidence of AEI. Assuming the true cell
type composition was known, among the 7,873 (70%) tested SNPs with AEI in the same direction,
we correctly uncovered 1,920 for the major cell type and 1,268 for the non-major cell type, with
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type I error well controlled at the 0.05 significance level. For the major cell type, the results were
similar as those obtained under the first scenario, indicating that the performance of BSCET was
not influenced much when more than one cell type had AEI. For the non-major cell type, due to
its lower expression level than the major cell type, the detection power, as expected, was lower
than that for the major cell type. Nevertheless, we still had around 80% power when the underlying
AEI was large, e.g., over 0.7, and the power difference between the major and non-major cell
types decreased as the AEI level increased. Among the 3,427 (30%) tested SNPs with opposite
directions in AEI, we correctly recovered the direction of cell-type-specific AEI for 2,330 SNPs
(68%), and identified 837 with AEI for the major cell type and 502 for the non-major cell type after
FDR adjustment. For both the major and non-major cell types, the patterns of type I error and
power are consistent with those observed in Figure 3.5A, suggesting that BSCET was reliable for
detecting cell-type-specific effect even when the two alleles of the transcribed SNP were regulated
differently across cell types (Figure 3.5B).
In comparison, among the 7,873 SNPs with AEI in the same direction, the bulk GLM method cor-
rectly identified 4,840 SNPs with AEI, of which 2,609 overlapped with findings by BSCET. Since
bulk-level AEI reflects the collective effect of AEI across all cell types, the bulk GLM method is ex-
pected to be more powerful when the goal is to detect the overall evidence of AEI. But still, BSCET
was able to detect an additional 578 SNPs with cell-type-specific AEI for the major cell type and
422 SNPs for the non-major cell type that were missed by the bulk method. For the 3,427 SNPs
with opposite AEI effects, the bulk GLM method detected 644 SNPs with AEI, and 444 of them
overlapped with those detected by BSCET. This time, the bulk detection method was less powerful
than BSCET, which was not surprising because the cell-type-specific AEI was neutralized when
expression was averaged across cell types. For SNPs with bulk AEI level between 0.45 and 0.55,
BSCET correctly uncovered many of them showing cell-type-specific AEI in both the major and non-
major cell types, while the GLM model failed to detect any, indicating that BSCET was able to reveal
cell-type-specific effect when the AEI was masked at the bulk level (Figure 3.6). When repeating
the same analysis but using the “estimated” cell type proportions as input for BSCET, for the 70%
SNPs with the same AEI direction, we identified 1,766 SNPs for the major cell type and 1,119 for
the non-major cell type after FDR adjustment, respectively. For the 30% SNPs with opposite AEI
effects, BSCET correctly detected 707 for the major cell type and 375 for the non-major cell type.
As expected, estimation uncertainty in cell type proportions slightly decreased BSCET’s detection
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Figure 3.5: Benchmark evaluation for cell-type-specific AEI detection assuming two cell types with
AEI
We evaluated the performance of BSCET assuming both the major and a non-major cell types had
AEI using true cell type proportions. For each gene, the major cell type was selected as the one
with the highest mean expression, and a non-major cell type was selected as the one with median
mean expression in scRNA-seq data (Baron et al., 2016). The AEI level for two cell types were
assumed to be in the same direction, i.e., their AEI levels are > 0.5 for both cell types, for 70% of
the SNPs, and in opposite directions, i.e., their AEI levels sum to 1, for the remaining 30% of the
SNPs. (A) Type I error rate and power evaluated separately by cell type and true level of AEI for the
70% SNPs with the same direction of AEI under significance level ↵ = 0.05 (dashed line) for the
major (left) and non-major cell types (right). (B) Type I error rate and power evaluated separately by
cell type and true level of AEI for the 30% SNPs with opposite directions of AEI under significance
level ↵ = 0.05 (dashed line) for the major (left) and non-major cell types (right). For each plot, the
number above each bar indicates the total number of genes with cell-type-specific AEI within the
category. The solid line indicates the overall power across all cell types.
power. But overall, the results were consistent with those using the true cell type proportions as
input with the correlation of p-values over 0.9 (Figure S3.2).
3.3.3. Detection of cell-type-specific differential AEI
We further evaluated the performance of BSCET for detecting covariate effect on cell-type-specific
AEI. We considered a case-control setting and assessed the effect of disease status on AEI, i.e.,
differential AEI (DAEI) between healthy and diseased samples. First, we considered equal num-
ber of cases and controls, i.e., non-diabetes and diabetes given the pancreatic islets data setting
(100 vs. 100). Figure 3.7A shows that BSCET did not generate excessive false positive results
for SNPs without cell-type-specific DAEI at the 0.05 significance level. When the difference of cell-
type-specific AEI between cases and controls was small, i.e., 0.1, using true cell type proportions
as input, among all 5,607 SNPs with cell-type-specific DAEI, BSCET identified 2,776 of them af-
ter multiple testing adjustment, whereas the bulk detection method uncovered 3,199 SNPs, with
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Figure 3.6: Benchmark comparison of BSCET and bulk GLM method assuming two cell types with
AEI
The benchmark data were generated assuming the major cell type and a non-major cell type had
AEI. Here we focused on the 30% SNPs with opposite AEI directions for the major and non-major
cell types, i.e., their AEIs sum to 1. We selected SNPs with small bulk-level AEI, i.e., within 0.45-
0.55, and plotted their bulk-level mean expression against the AEI, where the bulk-level AEI was
estimated as the reference allele proportion, i.e., the proportion of reference allele read count rela-
tive to the total count of both alleles of each SNP. We colored each SNP according to whether it was
detected as cell-type-specific AEI by BSCET only (green), AEI by the bulk detection method only
(blue), or by both methods (red). On each margin, using the same color scale, we used histogram
to show the distribution of bulk-level AEI (top) and mean expression level (right) for the SNPs.
2,136 overlapped with BSCET. When the differential AEI effect increased to 0.2, among the 5,655
SNPs with cell-type-specific DAEI, BSCET identified 4,370, while the bulk method identified 4,647,
of which 3,981 overlapped with BSCET. Similar to one condition analysis, under both scenarios,
SNPs uniquely detected by BSCET on average had lower sequencing depth as compared to SNPs
uniquely detected by the bulk method. For example, when the cell-type-specific DAEI was 0.1,
the mean read count for bulk-uniquely detected SNPs was 385.0 (IQR 133.4-479.8) and 98.4 (IQR
44.5-121.8) for BSCET-uniquely detected SNPs. The power decreased as the AEI level in controls
increased. This was as expected because given the same AEI difference between the two groups,
a higher AEI level in controls led to a lower effect size of the AEI difference.
In real studies, we often have less cases than controls. Thus, we also considered a scenario
assuming 60 cases versus 140 controls. Again, the type I error was under control. Compared to
results with balanced sampling, this scenario had lower detection power, but BSCET still correctly
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Figure S3.2: Benchmark evaluation for cell-type-specific AEI detection assuming two cell types
with AEI
The benchmark data were generated assuming the major cell type and a non-major cell type had
AEI. We evaluated the performance of BSCET using ”estimated” cell type proportions, where the
”estimated” proportions were obtained by adding random noise to the true proportions. BSCET
was evaluated separately for (A) SNPs with AEI level for two cell types in the same direction, i.e.,
both > 0.5 (70%) and (B) SNPs with AEI for two cell types in the opposite directions, i.e. sum
to 1 (30%). Within each scenario, we compared the SNP-level p-values obtained using true cell
type proportions versus those obtained using ”estimated” cell type proportions (left), and evaluated
the type I error rate and power, separated by the cell type and true AEI level, at significance level
↵ = 0.05 (dashed line) for the major (middle) and non-major cell type (right). The solid line indicates
the overall power across all cell types at each level of AEI.
detected 2,676 out of 5,641 SNPs with cell-type-specific DAEI when the true DAEI was 0.1, and
4,317 out of 5,656 when the true DAEI increased to 0.2 (Figure 3.7B). Additionally, when using
”estimated” cell type proportions as input, across all scenarios, the results were highly correlated
with those obtained using true cell type composition (Figure S3.3).
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Figure 3.7: Benchmark evaluation for cell-type-specific differential AEI (DAEI) detection
Using true cell type proportions, we evaluated the performance of BSCET as a function of sample
size for healthy (i.e., non-T2D) and diseased (i.e., T2D) samples, and true cell-type-specific AEI
difference between two-condition samples (0.1 (A) and 0.2 (B)). Type I error rate (non-DAEI) and
power (DAEI) were evaluated at significance level ↵ = 0.05 (dashed line), further separated by the
cell type and level of AEI in the healthy samples. The number above each bar indicates the total
number of SNPs with cell-type-specific DAEI within the category. The solid line indicates the overall
power across all cell types.
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Figure S3.3: Benchmark evaluation for cell-type-specific differential AEI (DAEI) detection
We evaluated the performance of BSCET as a function of sample size for healthy (i.e., non-T2D)
and diseased (i.e., T2D) samples, and true cell-type-specific AEI difference between healthy and
diseased samples (0.1 (A) and 0.2 (B)) using ”estimated” cell type proportions, where the ”esti-
mated” proportions were obtained by adding random noise to the true proportions. Within each
scenario, we compared the SNP-level p-values obtained using true cell type proportions versus
those obtained using the ”estimated” proportions through the scatter plot (top). And evaluated the
type I error rate (non-DAEI) and power (DAEI)), separated by the cell type and level of AEI in the
healthy samples, at significance level ↵ = 0.05 (dashed line) (bottom). The solid line indicates the
overall power across all cell types for each level of AEI in the healthy samples.
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3.3.4. Application to Fadista et al. human pancreatic islet bulk RNA-seq data
We applied BSCET to detect cell-type-specific AEI using human pancreatic islet bulk RNA-seq data
of 89 donors generated in an expression quantitative trait loci (eQTL) study by Fadista et al. (2014).
We chose to reanalyze this data because cell type composition vary across individuals (Wang et al.,
2019), which may confound the bulk-level AEI detection as one cannot tell whether the detected AEI
is true AEI or is simply due to variations in cell type composition among individuals. We focused our
analysis on four well-recognized cell types: acinar, alpha, beta and ductal. We first deconvolved the
bulk RNA-seq data by MuSiC (Wang et al., 2019) using the scRNA-seq data from six healthy donors
generated by Segerstolpe et al. (2016) as the reference. The estimated cell type proportions were
shown in Figure 3.8A. A SNP was included for analysis only if its minor allele count   5, total read
count for both alleles   20, minor allele count was at least 5% of the total read count and appeared
in at least 20 individuals. In total, we analyzed 5,972 SNPs across 2,909 genes using both BSCET
and the traditional GLM method for bulk AEI detection. After FDR adjustment, 283 SNPs across
129 genes were detected as having AEI for at least one cell type. Of the 129 genes, 121 (94%) were
identified while 8 (6%) were missed by the bulk method. The bulk method detected an additional
1,281 genes with AEI (Figure 3.8B). Similar to benchmark studies, the mean expression level was
higher for SNPs detected only by bulk analysis (mean reads 129.3 with IQR 36.8-101.5) than SNPs
detected only by BSCET (mean reads 46.7 with IQR 30.0-53.3).
Figure 3.8: Deconvolution and cell-type-specific AEI detection of the Fadista pancreatic islets
RNA-seq data
(A) Cell type proportion estimates of the Fadista et al. (2014) bulk RNA-seq data using MuSiC
(Wang et al., 2019). The Segerstolpe et al. (2016) scRNA-seq data were used as the reference.
(B) Venn diagram showed the total number of genes analyzed, and number of genes detected with
cell-type-specific AEI after FDR multiple testing adjustment using BSCET (green) and traditional
bulk AEI detection method based on GLM model (blue).
Next, we compared genes detected by BSCET with the 616 eGenes identified to have cis-eQTL
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SNPs by Fadista et al. (2014). Among the 616 eGenes, 56 were analyzed by BSCET, and 6 (11%)
were found to have cell-type-specific AEI. To evaluate if 11% overlapping was higher than expected
by chance, we performed resampling-based enrichment analysis. Specifically, we randomly sam-
pled 129 genes from the remaining 2,780 genes that did not show evidence of cell-type-specific
AEI by BSCET and recorded the percentage of genes overlapping with the 616 eGenes in Fadista
et al. (2014). By repeating this sampling procedure 10,000 times, we calculated the enrichment
p-value as #(presampled 11%)10,000 , which equaled to 0.029, suggesting that results from BSCET signifi-
cantly overlapped with the cis-eQTL findings.
For genes identified with cell-type-specific AEI by BSCET, some of them are cell-type-specific
marker genes by PanglaoDB (Franzén, Gan, and Björkegren, 2019). For example, CELA3A, with
two transcribed SNPs detected having cell-type-specific AEI by BSCET, is a marker gene for acinar
cells (Figure 3.9A), and BSCET only detected AEI in acinar cells but not in the other cell types,
confirming the specificity of BSCET. Furthermore, we uncovered two other marker genes for acinar
cells with cell-type-specific AEI, CPA2 and PRSS3. In addition to acinar cells, we also detected
a marker gene for beta cells with cell-type-specific AEI, EDARADD, which had consistent signals
across the majority of transcribed SNPs in this gene (Figure 3.9B).
Figure 3.9: Selected genes with cell-type-specific AEI of the Fadista pancreatic islets RNA-seq
data
We selected 4 genes, CELA3A (A), EDARADD (B), INSM1 (C) and CHGB (D), to show their SNP-
level p-values of cell-type-specific AEI. Within each cell type, different shapes represent different
SNPs of the gene, with red color indicating significant AEI after FDR multiple testing adjustment.
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For genes identified by BSCET but are not documented as marker genes by PanglaoDB (Franzén,
Gan, and Björkegren, 2019), we found many of them are biologically relevant. For example, INSM1
had cell-type-specific AEI for both alpha and beta cells with signals well agreed across both SNPs
analyzed for this gene (Figure 3.9C). Several studies have reported INSM1 as a key factor for the
development and differentiation in pancreatic beta cells (Gierl et al., 2006; Zhang et al., 2010).
Another example is CHGB, which had significant cell-type-specific AEI for beta cells by BSCET
(Figure 3.9D). A recent study has shown that CHGB is essential for regulating secretory granule
trafficking in beta cells (Bearrows et al., 2019). Several other genes identified by BSCET are also
known to have relevant functions. For example, PPM1K elevates branched-chain amino acids
concentrations and is related to high risk of T2D (Goni et al., 2017; Lotta et al., 2016). SYT11 has
been reported to be positively related to glucose stimulated insulin secretion in human pancreatic
islets (Andersson et al., 2012). ERO1B is known to encode a pancreas-specific disulfide oxidase
that promotes protein folding in pancreatic beta cells (Awazawa et al., 2014). AHR is expressed in
aortic endothelial cells and is activated in response to high glucose stimulation (Dabir et al., 2008)
(Figure S3.4).
Figure S3.4: Selected genes with cell-type-specific AEI of the Fadista pancreatic islets RNA-seq
data
We selected 6 genes, CPA2 (A), PRSS3 (B), PPM1K (C), SYT11 (D), ERO1B (E) and AHR (F) to
show their SNP-level p-values of cell-type-specific AEI detection using the Fadista et al. (2014) bulk
RNA-seq samples. The cell type proportions were obtained using MuSiC (Wang et al., 2019) based
on Segerstolpe et al. (2016) single-cell reference. Within each cell type, different shapes represent
different SNPs, with color red indicating significance AEI after FDR multiple testing adjustment.
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3.3.5. Evaluation on the impact of scRNA-seq reference
To examine whether BSCET is robust to the input cell type composition, we reanalyzed the Fadista
et al. (2014) bulk RNA-seq data using a different scRNA-seq dataset as reference. The new scRNA-
seq dataset was generated from three healthy donors by Baron et al. (2016). Cell type deconvolu-
tion using this scRNA-seq reference resulted in a much smaller proportion for beta cells compared
to results obtained using the Segerstolpe et al. (2016) scRNA-seq data as reference (Figure 3.10A).
Using the new cell type proportions as input for BSCET, we identified 148 out of 2,909 analyzed
genes to have cell-type-specific AEI after multiple testing adjustment, among which 102 were also
found in previous analysis when using the Segerstolpe et al. (2016) scRNA-seq data as reference.
Overall, the SNP level p-values obtained from these two different scRNA-seq reference datasets
were well correlated (R = 0.72, Figure 3.10B). Stratified by cell type, the correlation was the highest
for alpha cells (R = 0.87), followed by acinar (R = 0.81) and ductal (R = 0.77) cells. The correla-
tion for beta cells was moderate (R = 0.59), which can be explained by the large difference in the
estimated proportion of the beta cells when using the two single-cell datasets as reference (mean
proportion: 3% vs. 28%, Figure 3.10C). Overall, BSCET yielded relatively consistent results based
on the cell type composition of the bulk data deconvolved by referencing on different scRNA-seq
data, suggesting that our method is robust to the choice of single-cell reference for deconvolution.
3.3.6. Replication using Bunt et al. human pancreatic islet bulk RNA-seq data
We further applied BSCET to another pancreas islets RNA-seq data of an eQTL study generated
from 118 individuals by Bunt et al. (2015) using the Segerstolpe et al. (2016) scRNA-seq data
as reference. The estimated cell type composition are overall similar to the Fadista et al. (2014)
data, except for a smaller proportion for alpha cells (Figure 3.11). In total, we analyzed 9,013
SNPs across 4,293 genes, and detected 722 SNPs across 423 genes showing cell-type-specific
AEI after multiple testing adjustment. Next, we compared these results with those obtained from
the Fadista et al. (2014) data. Among the 48 genes detected with AEI for acinar cells in Fadista,
41 were analyzed in Bunt, among which 23 (56%) also showed acinar cell-specific AEI. Similarly,
for the 81 genes with AEI for beta cells in Fadista, 33 (41%) were replicated in Bunt. For ductal
cells, among the 27 genes with AEI in Fadista, 15 (56%) were replicated in Bunt. However, for
alpha cells, among the 39 genes detected in Fadista, only 6 genes (15%) were replicated in Bunt.
This is likely due to the large discrepancy in estimated cell type proportions for alpha cells between
the two datasets. Despite some difference, the AEI results obtained using the Bunt data validated
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Figure 3.10: Deconvolution and cell-type-specific AEI detection of the Fadista pancreatic islets
RNA-seq data
(A) Cell type proportion estimates of the Fadista et al. (2014) bulk RNA-seq data using MuSiC
(Wang et al., 2019) when the Baron et al. (2016) scRNA-seq data were used as the single-cell ref-
erence. (B and C) Scatterplot comparing the SNP-level p-values obtained using cell type proportion
estimates based on Segerstolpe et al. (2016) single-cell reference versus those obtained based on
Baron et al. (2016) scRNA-seq data across all cell types (B) and by each cell type (C).
findings obtained in Fadista. For example, PVR, also known as CD155, involves in the regulation
of T-cell activation and is associated with autoimmune diseases such as type 1 diabetes (T1D)
(Escalante et al., 2011; Lozano et al., 2013), had two SNPs showing AEI for ductal cells in Fadista.
This finding was confirmed in Bunt in multiple SNPs (Figure 3.12A). Similarly, we detected acinar
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and beta cell-specific AEI for several SNPs in gene SSR3 in both datasets (Figure 3.12B). Gene
SSR3 is involved in protein translocation across the endoplasmic reticulum (ER) membrane, whose
expression has showed to be related to T2D (Bensellam, Jonas, and Laybutt, 2017; Stelzer et al.,
2016). Moreover, gene GNPNAT1 was detected only for one SNP with acinar cell-specific AEI in
the Fadista, but was confirmed with much stronger effect in Bunt (Figure 3.12C). Previous studies
have shown that GNPNAT1 is associated with insulin secretion and diabetes (Bacos et al., 2016;
Walaszczyk et al., 2018).
Figure 3.11: Deconvolution of the Bunt pancreatic islets RNA-seq data
Cell type proportion estimates of the Bunt et al. (2015) bulk RNA-seq data using MuSiC (Wang
et al., 2019) when the Segerstolpe et al. (2016) scRNA-seq data were used as the single-cell
reference.
3.3.7. Association of cell-type-specific AEI with HbA1c level
Type 2 diabetes (T2D) is characterized by the progressive dysfunction of pancreas islets. Next,
we applied BSCET to explore the association between hemoglobin A1c (HbA1c), a well-known
biomarker for T2D diagnosis, and cell-type-specific AEI. People with higher HbA1c have great risk
of developing T2D (American, 2012). Using the Fadista bulk RNA-seq data, we focused our anal-
ysis on 77 samples with HbA1c level available. Figure 3.13A showed relationship between HbA1c
level and estimated cell type proportions with Segerstolpe et al. (2016) scRNA-seq data as ref-
erence. As expected, we observed a negative association between beta cell proportion and the
HbA1c level. After applying the same filtering criteria as described previously, we analyzed in to-
tal 5,021 SNPs across 2,570 genes, and identified 8 genes, HYOU1, PLA2G1B, CCDC32, CCL2,
CDC42EP3, LARS, SLC30A8 and CEL, whose cell-type-specific AEI is associated with HbA1c
level. By contrast, using traditional bulk AEI detection method, we detected 125 genes with sig-
nificant association between AEI and HbA1C level, and among which, LARS, SLC30A8 and CEL
overlapped with those detected by BSCET.
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Figure 3.12: Selected genes with cell-type-specific AEI of both pancreatic islet RNA-seq data
We selected 3 genes, PVR (A), SSR3 (B) and GNPNAT1 (C), to show their SNP-level p-values of
cell-type-specific AEI using two different bulk samples, Fadista et al. (2014) and Bunt et al. (2015).
Within each cell type, different shapes represent different SNPs of the gene, with red color indicating
significant AEI after FDR multiple testing adjustment.
BSCET revealed a negative association of HbA1c level with the acinar cell-specific AEI for SLC30A8
(Figure 3.13B). This is consistent with previous studies reporting that SLC30A8 encodes an islet
zinc transporter (ZnT8) and a reduced zinc transport can increase the risk of T2D (Pourvali, Abbasi,
and Mottaghi, 2016; Rutter, 2010). Moreover, a human study suggested that SLC30A8 haploinsuf-
ficiency helps protect against T2D (Flannick et al., 2014). To further validate our findings, we
repeated the analysis but using the cell type composition estimated with the Baron et al. (2016)
scRNA-seq data as reference (Figure S3.5A). After multiple testing adjustment, we identified 4
genes, CCDC32, LARS, SLC30A8 and CEL, whose cell-type-specific AEI was associated with
HbA1c level, and all were also detected when using the Segerstolpe et al. (2016) data as single-
cell reference. For SLA30A8, we observed a consistent negative association between acinar cell-
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Figure 3.13: Cell type composition and selected genes with cell-type-specific AEI associated with
the progression of T2D of the Fadiata pancreatic islets RNA-seq data
(A) HbA1c vs. estimated proportions of the Fadista et al. (2014) bulk RNA-seq data for each
cell type, where the proportions were estimated through MuSiC (Wang et al., 2019) based on the
Segerstolpe et al. (2016) single-cell reference. (B,C) We selected 2 genes, SLC30A8 (B) and CEL
(C), to show their SNP-level p-values of the association between HbA1c and cell-type-specific AEI,
where we used cell type proportion estimates obtained from two different scRNA-seq reference
datasets: Segerstolpe et al. (2016) and Baron et al. (2016). Within each cell type, different shapes
represent different SNPs. We used color red to indicate a positive correlation between HbA1c and
cell-type-specific AEI, with color brightness representing the significance after FDR adjustment.
Similarly, we used color blue to indicate a negative correlation between HbA1c and cell-type-specific
AEI, with color brightness representing the significance after FDR adjustment.
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specific AEI and HbA1c level. Similar negative association of acinar cell-specific AEI was detected
for another gene, CEL (Figure 3.13C), a marker gene for acinar cells in PanglaoDB (Franzén, Gan,
and Björkegren, 2019). Previous studies have reported that CEL mutations can lead to childhood-
onset pancreatic exocrine dysfunction and diabetes mellitus from adulthood (Johansson et al.,
2011; Torsvik et al., 2014). For the other two genes, CCDC32 and LARS, further investigations
are needed as little is known about their functions related to T2D (Figure S3.5).
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Figure S3.5: Cell type composition and selected genes with cell-type-specific AEI associated with
the progression of T2D in the Fadista pancreatic islets RNA-seq data
(A) HbA1c vs. estimated cell type proportions of the Fadista et al. (2014) bulk RNA-seq data for
each cell type, where the proportions were estimated by MuSiC (Wang et al., 2019) using the Baron
et al. (2016) scRNA-seq data as reference. (B and C) We selected 2 genes, CCDC32 (B) and LARS
(C), to show their SNP-level p-values of the association between HbA1c and cell-type-specific AEI
in Fadista et al. (2014) samples, where we used cell type proportion estimates obtained using two
different scRNA-seq datasets: Segerstolpe et al. (2016) and Baron et al. (2016). Within each cell
type, different shapes represent different SNPs. We used color red to indicate a positive correlation
between HbA1c and cell-type-specific AEI with color brightness representing the significance after
FDR adjustment. Similarly, we used color blue to indicate a negative correlation between HbA1c
and cell-type-specific AEI with color brightness representing the significance after FDR adjustment.
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3.4. Discussion
Detection of AEI is an important step towards the understanding of phenotypic variations associated
with gene expression differences across individuals. Traditionally, AEI is detected at the tissue level
using bulk RNA-seq data. However, solid tissue includes cells from different cell types and gene
expression variations are often cell-type-specific. Methods that detect AEI at the bulk tissue level
only capture the averaged effect of gene expression across cells, making it difficult to discern what
cell types are driving the AEI signal. Although it is possible to study cell-type-specific AEI using
scRNA-seq data, the high cost of scRNA-seq has limited its application in studies that involve a
large number of individuals. As bulk RNA-seq is more cost-effective and bulk RNA-seq data in
clinically relevant tissues are widely available, to better utilize existing bulk RNA-seq data and help
refine bulk-level AEI, we developed BSCET, a novel method that can detect cell-type-specific AEI
across individuals. BSCET is not aimed to replace traditional bulk AEI detection methods, but rather
is set to help elucidate in what cell types AEI is present. To gain a comprehensive understanding
of genetic polymorphisms on gene expression variation, we suggest analyzing the data using both
the traditional bulk tissue AEI detection methods and BSCET.
To detect cell-type-specific AEI at the population level, BSCET aggregates information across in-
dividuals of the same transcribed SNP. A major challenge for cross-individual AEI detection is the
difficulty of aligning allele-specific read counts, as the corresponding regulatory SNP for a given
gene is often not observed. In BSCET, we assumed the unobserved regulatory SNP is in complete
LD with the transcribed SNP, which allows us to align read counts from different individuals based
on alleles of the transcribed SNP. The aligned allelic read counts enabled the detection of AEI
across individuals at the population level. Through extensive benchmark evaluations, we showed
that BSCET had adequate power to detect moderate AEI at the cell type level. Through further ap-
plications to human pancreatic islet RNA-seq datasets, we demonstrated that the cell-type-specific
AEI uncovered by BSCET are biologically relevant to pancreatic functions and the progression of
T2D.
BSCET uses the estimated cell type proportions of bulk RNA-seq data as input. Ideally, if the true
cell type proportions are known, we would like to use them in order to obtain an accurate estimate
of cell-type-specific AEI. In the absence of true cell type proportions, we can estimate them using
cell-type deconvolution methods such as MuSiC (Wang et al., 2019), which borrows information
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from external scRNA-seq data to infer the cell type composition of a bulk RNA-seq sample. The
benchmark evaluations and real data applications showed that the results obtained using “esti-
mated” cell type proportions were highly correlated with those obtained using true proportions. We
further illustrated that, even though different scRNA-seq reference can lead to varied proportion es-
timates, such variations did not affect the BSCET results much as the detected AEI genes agreed
well, suggesting that BSCET is robust to estimation uncertainty on the input.
As a regression-based method, BSCET is flexible and can include covariates in the model and
evaluate how covariates would affect cell-type-specific AEI. We have demonstrated that BSCET
has adequate power to detect association between cell-type-specific AEI with covariates through
benchmark evaluations under a variety of scenarios. Further, we applied the extension model
to human pancreatic islet bulk RNA-seq data and detected genes whose cell-type-specific AEI is
associated with T2D progression. We note that as more parameters are included in the model, a
larger sample size is required. Therefore, we would recommend users to perform such analysis as
a supplemental step only after evidence of cell-type-specific AEI is detected in at least one of the
two groups or in all individuals in the data.
In summary, we have developed BSCET, a regression-based method that integrates bulk RNA-seq
and scRNA-seq data to detect cell-type-specific AEI across individuals. BSCET refines the current
bulk-level AEI detection workflow and helps understand gene regulation and its association with
phenotypic variations across individuals at cell type resolution. As bulk RNA-seq is widely adopted
by many biomedical studies and more samples are being sequenced, instead of newly generating
large samples using scRNA-seq technology, it is desirable for researchers to fully utilize the existing
bulk RNA-seq data and learn a comprehensive picture of allelic imbalance in a more cost-effective
way. We believe BSCET, which, to the best of our knowledge, is the first method using bulk RNA-
seq data to detect cell-type-specific AEI, will be a great supplemental tool for utilizing the easily
accessible bulk sequencing data to elucidate cell type contributions in human diseases.
64
CHAPTER 4
MUSIC2: CELL TYPE DECONVOLUTION FOR MULTI-CONDITION BULK RNA
SEQUENCING DATA
4.1. Introduction
Bulk tissue RNA sequencing technology has been widely adopted to investigate gene expression
variations that underlie phenotypic differences among individuals. Findings from these studies have
facilitated the identification of therapeutic targets for human diseases. Bulk RNA-seq measures the
average gene expression across cells in a tissue and ignores the possible cell-to-cell heterogene-
ity in the tissue. It is well known that variations not only exist in gene expression patterns across
different cell types, but also in cell type compositions of different samples. Knowledge in cell type
composition and its changes during disease progression is an important step towards understand-
ing disease pathogenesis (Donovan et al., 2020; Inkeles et al., 2016; Newman et al., 2019). Since
certain cell types are more vulnerable to diseases than others (Handley et al., 2015; Shen-Orr et al.,
2010), it is important to account for cell type composition variations in bulk RNA-seq data analysis
to avoid biasing downstream results (Jaffe and Irizarry, 2014).
A number of deconvolution methods have been developed to estimate cell type compositions using
scRNA-seq data as reference (Li and Wu, 2019; Newman et al., 2015; Wang et al., 2019). A
key assumption of these methods is that the bulk samples and scRNA-seq reference samples are
from the same population so that the cell-type-specific gene expression observed in the scRNA-
seq data can be used to approximate the unobserved cell-type-specific gene expression in the bulk
samples. This assumption is reasonable when the bulk and scRNA-seq samples are collected
from individuals of similar clinical condition. However, when the bulk samples are collected from a
different condition as compared to the scRNA-seq samples, this assumption becomes questionable.
Most existing scRNA-seq data were generated from tissues of healthy donors. When using such
data as reference to deconvolve bulk RNA-seq samples collected from diseased subjects (Baron et
al., 2016; Newman et al., 2019; Wang et al., 2019), the estimated cell type compositions might not
be accurate and bias downstream analysis due to potential differences in cell-type-specific gene
expression between healthy and diseased samples. To better integrate bulk RNA-seq and scRNA-
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seq data, improved deconvolution methods that are robust to the choice of scRNA-seq reference
are needed.
To obtain valid cell type proportion estimates, we proposed MuSiC2 to perform deconvolution anal-
ysis of bulk RNA-seq data using a scRNA-seq reference data generated from a condition that
differs from the bulk data. The key idea is to identify genes showing cell-type-specific differential
expression (DE) between different clinical conditions. By iteratively removing those genes from
the single-cell reference, MuSiC2 improves feature selection for deconvolution and achieves more
accurate cell type proportion estimation.
Through extensive benchmark evaluations, we demonstrate that MuSiC2 improved cell type pro-
portion estimation of multi-condition bulk RNA-seq samples as compared to MuSiC (Wang et al.,
2019), which ignored condition difference between the bulk data and single-cell reference. We fur-
ther applied MuSiC2 to pancreatic islets bulk RNA-seq data and correctly recovered the trend of cell
type proportion changes as type 2 diabetes progressed. With the wide application of large-scale
bulk tissue RNA-seq in biomedical studies under different diseased conditions, MuSiC2 allows the
utilization of existing bulk RNA-seq data to elucidate cell type contributions and identify cellular
targets of human diseases.
4.2. Materials and Methods
4.2.1. Methods overview
MuSiC2 is an iterative algorithm aiming to improve cell type deconvolution for bulk RNA-seq data
using a scRNA-seq as reference when the bulk and scRNA-seq data are generated from sam-
ples with different clinical conditions (e.g., diseased and healthy). It takes two datasets as input,
a bulk RNA-seq dataset collected from samples with multiple conditions and a scRNA-seq dataset
generated from a single condition, e.g., healthy. The key idea of MuSiC2 is that, when the bulk
samples and single-cell reference samples are from different clinical conditions, the majority of
genes shall still have similar cell-type-specific gene expression pattern between conditions. We re-
fer those genes as ”stable” genes. By removing genes with cell-type-specific differential expression
(DE) between samples with different clinical conditions from the single-cell reference, the model
assumption for cell type deconvolution is met, and hence holds the potential to yield more accurate
cell type proportion estimates. By alternating between cell type deconvolution (step 1) and cell-
type-specific DE gene detection and removal (step 2), MuSiC2 gradually refines the list of ”stable”
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genes retained in the scRNA-seq reference and improves the cell type proportion estimation. An
overview of MuSiC2 is shown in Figure 4.1.
Figure 4.1: Overview of MuSiC2
The method takes a bulk RNA-seq dataset that includes samples from multiple clinical conditions,
e.g., healthy and diseased, and a scRNA-seq dataset that includes samples from a single condition,
e.g., healthy, as input. MuSiC2 iterates over steps 1 and 2 and achieves accurate cell type propor-
tion estimation after the algorithm converges. In step 1, under each condition, we employ MuSiC
(Wang et al., 2019) to infer the cell type proportions, pk
j
, of the bulk tissue for individual j of cell type
k by borrowing information from scRNA-seq reference data from healthy subjects. When decon-
volving healthy bulk samples, all genes in the single-cell reference are used, whereas only retained
”stable” genes are used for diseased samples. At the initial step, all genes are included for cell type
deconvolution in step 1. In step 2, for samples within each condition (healthy and diseased), we
model bulk-level expression of gene g across individuals over the estimated cell type composition
from step 1, pk
j
, through non-negative least square regression to infer the cell-type-specific mean
expression, µk
g




, we can identify genes with cell-type-specific
DE between the two conditions. We then update the gene list in the scRNA-seq reference used in
step 1 by removing those cell-type-specific DE genes for the diseased sample deconvolution.
4.2.2. Step 1: Estimating cell type proportions by deconvolution
In this step, we infer cell type proportions of bulk RNA-seq samples under each condition by in-
corporating cell-type-specific gene expression information provided by the scRNA-seq reference
collected from healthy samples. Following MuSiC (Wang et al., 2019), for samples under each con-
dition, the bulk-level total read count of gene g for individual j, Xjg, can be written as a weighted














where, for individual j, mj is the total number of cells in the tissue for bulk RNA-seq, pkj is the
proportion of cells from cell type k, Sk
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is the average cell size of cell type k, and ✓k
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can be approximated by the sample average Sk and ✓k
g
. By modeling the
total expression across genes, Xjg (g = 1, . . . , G), over Sk and ✓kg , the subject-specific cell type
proportion, pk
j
, can be estimated through weighted non-negative least squares regression.
For healthy bulk RNA-seq samples, as the scRNA-seq data are also generated from healthy sub-
jects, we use all genes in the single-cell reference for deconvolution by MuSiC (Wang et al., 2019).
For diseased samples, due to potential discrepancy in cell-type-specific gene expression profiles
between bulk RNA-seq and scRNA-seq samples, we only use those ”stable” genes in the single-cell
reference for deconvolution. A ”stable” gene is defined as a gene that has similar gene expression
profiles across all cell types between the bulk and scRNA-seq samples. The key for deconvolution
for diseased samples lies in the selection of those ”stable” genes.
4.2.3. Step 2: Detecting cell-type-specific DE genes
In this step, using the cell type proportion estimates obtained in step 1, for each gene under each
condition, we infer its mean expression for each cell type and determine if this gene shows any
evidence of differential expression (DE) in a given cell type. For bulk RNA-seq samples under each
condition, the bulk-level total read counts, Xjg,healthy and Xjg,diseased, can be written as weighted























are the mean expression of gene g for cell type k under healthy
and diseased conditions, respectively. For healthy samples, as µk
g,healthy
should be   0, for a given
gene g, it can be inferred through a weighted non-negative least squares regression by modeling the
bulk-level expression across all individuals, Xjg,healthy (j = 1, . . . , Nhealthy), on the estimated cell
type proportions from step 1, pk
j,healthy
. For diseased samples, µk
g,diseased
can be inferred similarly.
For a given gene g in cell type k, we use log fold change of cell-type-specific expression between
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), to estimate the cell-type-specific DE by employing a bootstrap
procedure to achieve a reliable estimate. Specifically, at each bootstrap iteration, we randomly
select a subset of samples without replacement under each condition, keeping the sampling pro-
portion the same between conditions, and compute logFC. We define a statistic T = |mean(logFC)
sd(logFC) |
as a measure of the cell-type-specific DE. Genes with T in the top 5% for common cell types, i.e.,
cell types with average proportion   10%, or in the top 1% for rare cell types, i.e., cell types with
average proportion < 10%, are considered as cell-type-specific DE genes. Since fold change is
sensitive for genes with low expression, we further filter the identified cell-type-specific DE genes





over the bootstrapped samples, and prune the cell-type-specific DE
gene list by removing genes with cell-type-specific expression in the bottom 5% for samples in both
conditions.
After cell-type-specific DE genes are identified, we then remove them from the original single-cell
reference. The updated scRNA-seq data are then used for deconvolution for the diseased samples
in step 1. Iterating through the deconvolution and feature selection steps, MuSiC2 gradually refines
the ”stable” gene set and eventually achieves accurate cell type proportion estimates after the
algorithm converges.
4.2.4. Benchmark bulk RNA-seq data generation
To evaluate the performance of MuSiC2, we constructed benchmark bulk RNA-seq data in which
the cell type proportions for each cell type are known, using a publicly available scRNA-seq dataset
on human pancreatic islets generated from 6 healthy individuals and 4 type 2 diabetes (T2D) pa-
tients (Segerstolpe et al., 2016). We evaluated the performance of MuSiC2 as a function of sample
size and cell type proportions. For each condition, the number of individuals was set to be 20,
50 or 100. For each individual in the benchmark bulk RNA-seq data, we generated 5,000 single
cells from six selected cell types, including acinar, alpha, beta, delta, ductal and gamma, with cell
type proportions generated from a Dirichlet distribution, where the distribution was assumed to be
either the same or different between healthy and diseased samples. To generate realistic cell type
proportions that mimic what are seen in real data, we estimated cell type proportions in the T2D
bulk RNA-seq samples using the T2D single-cell data as reference. These estimated cell type pro-
portions were then set as the mean parameters of the Dirichlet distribution used to generate the
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cell type proportions for diseased samples. For healthy samples, their cell type proportions were
generated from another Dirichlet distribution in which the mean parameters were determined by the
estimated cell type proportions when deconvolving the healthy bulk islets samples using the healthy
single-cell data as reference (Figure 4.2A). For situations when the healthy and diseased samples
have the same cell type proportion distribution, the mean parameters of the Dirichlet distribution
were set to be the average cell type proportion estimates obtained from the healthy bulk RNA-seq
data deconvolution.
Figure 4.2: Benchmark evaluation data generation scheme
(A) Cell type compositions for the artificial bulk RNA-deq data under two conditions. Here, we
assumed the cell type compositions were different between healthy and T2D samples. For each
cell type, the solid line represents the average cell type proportions across samples, which was
inferred through bulk data deconvolution. (B) Data generation scheme for obtaining the artificial
bulk RNA-seq data. Given gene g, for each cell type k, we first inferred the condition-specific mean
expression level from the single-cell data (Segerstolpe et al., 2016). We then sampled the subject-
specific mean expression through Poisson distribution with the inferred mean as the rate parameter.
Another layer of Poisson sampling was employed to obtain the total read count of each cell c for
each condition samples by using subject-specific mean as the rate. The artificial bulk RNA-seq
data was obtained by summing up read counts across all cells.
For each cell, we simulated read counts for 10,000 genes, which were randomly selected from
genes that were expressed in at least 30 cells in the scRNA-seq data (Segerstolpe et al., 2016).
Figure 4.2B shows the overall workflow for benchmark data generation. Briefly, to simulate data
for healthy samples, for each gene, we obtained the average cell-type-specific gene expression
across cells from 6 healthy donors in the scRNA-seq data (Segerstolpe et al., 2016). The subject-
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specific mean expression was sampled from a Poisson distribution with mean set to the inferred
cell-type-specific mean expression from the single-cell data. To generate cell-specific total read
counts for each individual, we sampled from another Poisson distribution in which the mean was
determined by the subject-specific mean expression. By summing up total read counts across
all cells, we obtained the benchmark bulk-level gene expression data. Following the same data
generation scheme, we simulated benchmark bulk RNA-seq data for diseased individuals based
on the scRNA-seq data from the 4 T2D donors (Segerstolpe et al., 2016).
4.2.5. Evaluation metrics
For individual j, denote the true cell type proportions as pj and estimated cell type proportions as
p̂j , where pj and p̂j are vectors with length K. We evaluated the deconvolution methods using the
following metrics:
(i) Estimation bias = p̂j   pj
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We performed benchmark studies to evaluate the performance of MuSiC2. The benchmark bulk
RNA-seq data included healthy and diseased (i.e. T2D) samples generated from a human pancre-
atic islet scRNA-seq dataset (Segerstolpe et al., 2016), with known cell type proportions under each
condition. Only the healthy samples from the islets scRNA-seq data (Segerstolpe et al., 2016) were
used as the single-cell reference. As a comparison, we also performed the deconvolution analysis
using MuSiC (Wang et al., 2019), referencing on either healthy or diseased single-cell data.
We evaluated the performance of MuSiC2 as a function of sample size, which took values of 20, 50
and 100 per condition. We considered two scenarios: one assumed the distribution of cell type com-
positions to be different between healthy and diseased samples, and the other assumed the same
distribution for the two conditions. Under each scenario, the estimated cell type proportions were
compared to the true proportions to evaluate the accuracy of the deconvolution methods. Specif-
ically we compared three situations: using MuSiC (Wang et al., 2019) and MuSiC2 with healthy
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scRNA-seq data as reference to deconvolve bulk RNA-seq data from healthy and from diseased
individuals, and using MuSiC (Wang et al., 2019) with diseased scRNA-seq data as reference to
deconvolve bulk data from healthy and from diseased individuals.
We first considered the scenario where the cell type compositions were assumed different between
conditions. When using healthy scRNA-seq data as reference to deconvolve healthy individuals,
as expected, MuSiC (Wang et al., 2019) and MuSiC2 had exactly the same performance with es-
timation bias close to 0. In contrast, when using diseased scRNA-seq data as reference, MuSiC
generated biased proportion estimates. When using healthy single-cell as reference to deconvolve
the diseased samples, compared to MuSiC, MuSiC2 improved the estimation accuracy for most of
the cell types, particularly for beta cells. For this common cell type in islets, MuSiC2 produced much
more accurate cell type proportion estimates than MuSiC (Wang et al., 2019), which suffered from
severe underestimation. For acinar and ductal cells, MuSiC2 achieved a comparable performance
as MuSiC (Wang et al., 2019). Interestingly, when the diseased bulk samples were deconvolved
using single-cell reference obtained from diseased samples, MuSiC (Wang et al., 2019) outper-
formed MuSiC2 with reduced estimation bias for beta, delta and gamma cells. However, for alpha
and ductal cells, the performance of MuSiC (Wang et al., 2019) was worse than the situation when
using healthy scRNA-seq reference to devonvolve the diseased samples. We suspect the reduced
accuracy of MuSiC for alpha and ductal cells are likely due to large variation in cell-type-specific
expression among diseased individuals in the single-cell reference data. This suggests that we may
not necessarily achieve accurate proportion estimates when using scRNA-seq reference generated
from similar clinical condition as the bulk RNA-seq samples (Figure 4.3A), which underscores the
importance of appropriate gene selection for deconvolution.
Next we focused only on the deconvolution results for diseased bulk samples. When sample size
for diseased individuals (NT2D) varied, we noticed that MuSiC2 had a comparable performance in
terms of the root mean square error (RMSE) and Jensen–Shannon divergence (JSD) per individ-
ual. Compared to MuSiC (Wang et al., 2019) when using healthy single-cell reference, MuSiC2,
on average, reduced the RMSE and JSD by nearly 50%, and with diseased single-cell reference,
MuSiC2 still achieved a slightly lower median RMSE. On the contrary, JSD for MuSiC (Wang
et al., 2019) referencing on diseased scRNA-seq data was the lowest among all three situations,
suggesting that the resulted cell type composition estimates had the highest similarity with true cell
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type proportions in terms of the overall distribution (Figure 4.3B&C).
Under the scenario where cell type proportions were assumed similar between conditions, the
pattern of estimation bias across cell types for all three situations were largely consistent with
the results observed previously when assuming different cell type proportion distributions between
conditions, but with slightly less improved accuracy on beta cells proportion estimates by MuSiC2
(Figure 4.4A). In addition, when considering only the diseased samples, similar to the first scenario
where the cell type compositions were different between conditions, MuSiC2 greatly improved the
RMSE and JSD as compared to MuSiC (Wang et al., 2019) with healthy single-cell reference,
suggesting that the performance of MuSiC2 is consistent regardless of the cell type composition
distributions between the two-condition samples. However, for this scenario, MuSiC (Wang et al.,
2019), with diseased scRNA-seq reference, achieved the best performance evaluated by RMSE
and JSD among all three situations (Figure 4.4B&C).
We also evaluated the replicability of MuSiC2 by applying MuSiC2 to the same benchmark bulk
RNA-seq samples twice. We found that results between two different runs were highly correlated,
with an average Pearson correlation coefficient across samples around 0.995 when number of
diseased samples equals to 50 or 100, and 0.987 when the number of diseased samples reduced
to 20.
4.3.2. Application to Fadista et al. human pancreatic islet bulk RNA-seq data
We applied MuSiC2 to human pancreatic islet bulk RNA-seq data generated in an expression quan-
titative trait loci (eQTL) study by Fadista et al. (2014). We chose to reanalyze this data because
previous study used scRNA-seq data from healthy donors to deconvolve all individuals regardless
of their disease status (Wang et al., 2019). As shown by our benchmark evaluations, deconvolving
diseased samples using healthy single-cell reference may yield biased proportion estimates and
such bias may propagate further in downstream analysis. We focused our analysis on 77 samples
with measured hemoglobin A1c (HbA1c), a well-known biomarker for T2D with higher HbA1c level
indicating higher risk of T2D. We defined an individual as T2D if HbA1c   5.7. We chose 5.7 rather
than the traditional value of 6.5 as the cutoff in order to have enough diseased samples. In addition,
individuals with HbA1c   5.7 are generally defined as prediabetes and their gene expression pro-
files may start differing from healthy subjects (Buysschaert et al., 2016; Heianza et al., 2011). With
this definition of T2D, we ended up with 39 healthy and 38 T2D samples. Six well-recognized cell
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Figure 4.3: Estimation accuracy of benchmark datasets
We evaluated the performance of three situations, using MuSiC2, MuSiC (Wang et al., 2019) with
healthy scRNA-seq reference and using MuSiC (Wang et al., 2019) with diseased scRNA-seq refer-
ence, under the scenario where the cell type compositions were assumed different between healthy
and diseased (i.e. T2D) samples. (A) Estimation bias between MuSiC2 and MuSiC (Wang et al.,
2019) for healthy and T2D samples, separated by cell types, with 100 individuals per condition.
(B) Individual-level root mean square error (RMSE) for T2D samples between MuSiC2 and Mu-
SiC (Wang et al., 2019) as a function of number of T2D samples (NT2D). (C) Individual-level
Jensen–Shannon divergence (JSD) for T2D samples between MuSiC2 and MuSiC (Wang et al.,
2019) as a function of sample size (NT2D).
types were selected: acinar, alpha, beta, delta, ductal and gamma, and scRNA-seq data generated
from six healthy donors by Segerstolpe et al. (2016) were used as the reference.
Figure 4.5 showed the estimated cell type proportions by MuSiC2. Since people with higher HbA1c
have greater risk of developing T2D, we expect to see a negative association between HbA1c levels
and beta cell proportions as beta cells are gradually lost during T2D. MuSiC2 successfully recov-
ered the significant negative association between beta cell proportions and HbA1c levels (p-value
= 0.00174). In addition, we repeated the same analysis and found that although individuals may
converged in different order within different runs, the estimated cell type proportions for diseased
samples were highly correlated (average Pearson correlation R = 0.988), suggesting that the boot-
strap sampling variation has little impact on the estimation.
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Figure 4.4: Estimation accuracy of benchmark datasets
We evaluated the performance of three situations, using MuSiC2, MuSiC (Wang et al., 2019) with
healthy scRNA-seq reference and using MuSiC (Wang et al., 2019) with diseased scRNA-seq ref-
erence, under the scenario where the cell type composition were assumed to follow similar distri-
bution between healthy and diseased (i.e. T2D) samples. (A) Estimation bias between MuSiC2
and MuSiC (Wang et al., 2019) for healthy and T2D samples, separated by cell types, with 100
individuals per condition. (B) Individual-level root mean square error (RMSE) for T2D samples be-
tween MuSiC2 and MuSiC (Wang et al., 2019) as a function of number of T2D samples (NT2D). (C)
Individual-level Jensen–Shannon divergence (JSD) for T2D samples between MuSiC2 and MuSiC
(Wang et al., 2019) as a function of sample size (NT2D).
Figure 4.5: Cell type composition of the Fadiata pancreatic islets RNA-seq data
HbA1c vs. estimated proportions of the Fadista et al. (2014) bulk RNA-seq samples for each cell
type, where the proportions were estimated through MuSiC2 based on the Segerstolpe et al. (2016)
single-cell reference of healthy donors.
4.4. Discussion
Insights into cellular heterogeneity and their composition in diseased relevant tissues are crucial for
understanding cell-type-specific gene expression variations associated with disease progression
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and can help identify cellular targets of disease. Existing cell type deconvolution methods are based
on the assumption that bulk and single-cell RNA-seq data are generated from samples under similar
clinical conditions and therefore have similar cell-type-specific expression profiles. However, due to
the potential difficulty of scRNA sequencing, only limited number of scRNA-seq data are available,
with majority of them generated from healthy individuals. Lack of diseased single-cell data, most
of the current deconvolution analyses inferred the cell type proportions of the bulk RNA-seq data
using single-cell reference sequenced from healthy samples, ignoring the disease status of the bulk
tissue samples. This could potentially result in biased cell type proportion estimates. To address
this issue and to better utilize existing multi-condition bulk RNA-seq data, we proposed MuSiC2, an
iterative algorithm, to deconvolve bulk RNA-seq data using single-cell reference generated under a
different condition.
MuSiC2 iterates over deconvolution and cell-type-specific DE genes detection. The key idea is
that by removing genes with different expression profiles between healthy and diseased conditions
from the healthy single-cell reference, we can use the rest of the genes to deconvolve diseased
bulk samples. Over iterations, MuSiC2 refines cell-type-specific DE genes identification and sub-
sequently improves the cell type proportion estimation. Through extensive benchmark evaluations
and application to a pancreatic islets dataset, we showed that our method yielded accurate cell
type proportion estimates when the bulk and single-cell reference data were generated from sam-
ple with different disease status. One advantage of MuSiC2 is that it does not require large sample
size to achieve a reasonably good performance. As shown in benchmark evaluations, when sample
size was as small as 20, MuSiC2 performed similarly well as sample size of 100. In addition, it is
important to note that, in MuSiC2, the criteria for defining cell-type-specific DE genes were purely
data-driven, which gives the users great flexibility of making their own definition of DE genes that is
appropriate to their research context.
In summary, we have developed MuSiC2, an iterative workflow to perform multi-condition bulk RNA-
seq data deconvolution using scRNA-seq data from a single condition. MuSiC2 improves current
deconvolution methods and provides a more accurate cell type proportion estimates when the bulk
and single-cell reference differ in clinical conditions. To understand the cellular targets of disease,
comparing to generating scRNA-seq data on large samples, deconvolution of bulk RNA-seq data
is attractive as bulk RNA sequencing is cost-effective and many data are already available. To the
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best of our knowledge, MuSiC2 is the first deconvolution method that deals with the situation where
the bulk and single-cell RNA-seq data are generated from samples with different clinical conditions.




SUMMARY AND FUTURE WORK
In this dissertation, I have developed a series of statistical methods to address challenges in de-
tecting allelic imbalance in gene expression using RNA-seq data. Existing ASE detection methods,
at best, aggregate ASE effect across multiple SNPs and infer gene-level ASE for a single individ-
ual. Since ASE findings may vary among individuals, individual-based analysis can complicate the
interpretation when the goal is to make a conclusion across individuals at the population level. As
evidence of ASE is often shared across individuals, to leverage information simultaneously across
multiple individuals and multiple SNPs within the same gene, in Chapter 2, we developed ASEP, a
method that can detect allelic imbalance in gene expression across individuals under one condition,
and differential ASE between two conditions. Through benchmark evaluations and applications to
kidney and macrophages data, we have demonstrated the convincing performance of ASEP, which
not only leads to easier interpretation, but also results in improved power as compared to traditional
individual-based ASE detection methods.
Although ASEP improves the bulk-level ASE detection, since gene expression has been shown
to be cell-type-specific, it is possible that only certain cell types are more vulnerable for disease.
To gain further insight into cell-type-specific gene regulation in a cost-effective way, in Chapter 3,
we proposed BSCET, which integrates bulk RNA-seq and single-cell RNA-seq data to detect cell-
type-specific allelic expression imbalance. The key idea is that if cell type compositions of the bulk
RNA-seq samples are available, the bulk-level expression can be deconvolved into each cell type
and the cell-type-specific ASE can be inferred accordingly. In real studies, the cell type proportions
can be estimated using deconvolution algorithms. Comprehensive benchmark evaluations and
real data applications to pancreatic islets data have shown that BSCET was robust to estimation
uncertainty in cell type proportions and can complement traditional bulk ASE detection method to
help elucidate in what cell types ASE is present.
BSCET relies on estimated cell type proportions as input. Due to the lack of scRNA-seq data
under diseased condition, deconvolving diseased bulk RNA-seq data using single-cell data ob-
tained from healthy samples as reference may fail to provide accurate proportion estimates and
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bias downstream analysis. This bias is due to the potential difference in cell-type-specific gene
expression between different clinical conditions. To address this issue, in Chapter 4, we proposed
MuSiC2 to perform multi-condition bulk RNA-seq data deconvolution using the scRNA-seq data
from a single condition as the reference. The main idea is to first identify genes showing cell-type-
specific differential expression (DE) between conditions. By removing those DE genes from the
single-cell reference, we are able to refine cell type proportion estimates for the unmatched bulk
samples. Benchmark studies and application to pancreatic islets RNA-seq data have demonstrated
that, through iterations, MuSiC2 can improve feature selection and achieve more accurate cell type
proportion estimates as compared to traditional deconvolution methods.
MuSiC2 was only evaluated under scenarios where the bulk and single-cell samples are sequenced
from the same species. However, as there are more scRNA-seq data available for animal studies
than human studies, the same workflow can be applied to cross-species deconvolution. For future
work, we plan to extend MuSiC2 to this setting, e.g., deconvolving human bulk RNA-seq data using
mouse single-cell reference. In addition, the current implementation of MuSiC2 can only handle
bulk data under two discrete conditions, e.g., diseased vs. healthy. However, in reality, diseases
progress continuously and it is often hard to define clear disease stages based on quantitative
clinical measures. For example, HbA1c measures the glucose level and is used to characterize
the risk of type 2 diabetes. It is possible that cell-type-specific gene expression changes along
with the HbA1c level as disease progresses. Information may be lost by simply dichotomizing the
HbA1c level by a cutoff. To overcome this limitation, we plan to modify MuSiC2 by identifying genes
whose cell-type-specific expression is significantly associated with continuous clinical covariates as
measures of disease progression.
RNA sequencing has revolutionized biomedical research and our understanding of the transcrip-
tome. Through quantitatively measuring gene expression, researchers are able to study the effect
of gene regulation and its relation with diseases. In this dissertation, I presented three statistical
methods that leverage existing bulk RNA-seq data to study allelic expression imbalance in a more
cost-effective way. With the wide application of RNA sequencing in biomedical studies, I believe the
proposed methods will help researchers uncover candidate genes linked to human diseases.
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